Top

Jared K. Burks, Ph.D.

Department of Hematopoietic Biology & Malignancy, Division of Cancer Medicine

About Dr. Burks

I started my career in science as a research assistant in Dr. Max D. Summers’ laboratory. We studied protein trafficking in baculovirus-infected cells where I became familiar with, and interested in, spinning-disk confocal imaging. This led to my enrollment in several imaging courses, and ultimately my entry into graduate school and back to Dr. Summers’ laboratory. During my PhD training, Dr. Summers placed me in charge of the confocal microscope, where I trained every user and developed imaging assays as a basic core service. Ultimately, I ended up identifying importin-alpha-16, which is a shuttling protein involved in moving integral membrane proteins through the lateral channel of the nuclear pore complex. This was based in large part on my previous imaging experiments with BV/ODV E26, which was identified as a viral homolog to the eukaryotic importin-alpha-16. After completing my PhD, I joined Dr. Xing Li Wang’s group at Baylor, where I continued to study viral protein trafficking in infected cells. In doing so, I also learned how to interact with people from other cultures and how to collaborate on a larger scale. I also mastered extensive problem-solving skills that allowed me to determine where technical errors were made in our research efforts, which facilitated in my resolving them quickly and efficiently. I found that I enjoyed this type of technical problem solving, albeit I was not able to perform as much imaging work as I had anticipated. Therefore, after my postdoctoral work, I sought employment in a shared resource facility that specialized in imaging. I secured a position with the Flow Cytometry and Cellular Imaging Core Facility at MD Anderson Cancer Center where I have flourished. In fact, I am now an Associate Professor and Co-Director of the facility. I have brought eight color imaging to the Institution through the use of FFPE sampling and multispectral microscopy. I have also introduced and established mass cytometry, CyTOF, (imaging and suspension) to our Institution. The latest iteration of CyTOF technology is imaging-based. It uses laser ablation to free material from the slide for analysis through the CyTOF. My other focus is on live cell spinning disk confocal imaging. This has been a need for some time among MD Anderson Cancer Center researchers. Through my actions with these technologies I sought fund and was awarded an NIH R50 research specialist grant. I continue to focus on these technologies as we examine the spatial distribution of cells in tissues of the tumor microenvironment. I wish to understand the functional interactions that occur in unique spatial niche. My strengths have always been, and continue to be, that I am technically trained to identify, adapt, and utilize emerging technologies to answer critical questions in cutting-edge research here at MD Anderson Cancer Center and elsewhere in the scientific community. We tackle these problems every day at the Flow Cytometry and Cellular Imaging Core Facility at MD Anderson, and we jointly develop solutions with our research collaborators to produce outstanding scientific discoveries.

Spatial biology with Dr. Jared Burks

What is spatial biology? See how different cell types in our tissues are interconnected.

Present Title & Affiliation

Primary Appointment

Director, Flow Cytometry & Cell Imaging Core Facility, Department of Hematopoietic Biology & Malignancies, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Associate Director of Shared Resources CCSG, Department of CCSG, The University of Texas MD Anderson Cancer Center, Houston, Texas

Professor, Department of Hematopoietic Biology & Malignancies, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX

Research Interests

Spatial imaging

Mass Cytometry

Imaging Mass Cytometry

Live cell imaging

Confocal Imaging

Education & Training

Degree-Granting Education

2005	Texas A&M University, College Station, Texas, US, Biology, Ph.D
1995	Florida Institute of Technology, Melbourne, Florida, US, Molecular Biology, BS
1995	Florida Institute of Technology, Melbourne, Florida, US, Pre-Professional Biology, BS

Postgraduate Training

2006-2007

Postdoctoral Associate, Baylor College of Medicine, Houston, Texas

Experience & Service

Other Appointments/Responsibilities

Director, Flow Cytometry & Cellular Imaging Core Facility, The University of Texas MD Anderson Cancer Center, Houston, TX, 2025 - Present

Professor, The University of Texas MD Anderson Cancer Center, Houston, TX, 2025 - Present

Associate Director Shared Resources CCSG, The University of Texas MD Anderson Cancer Center, Houston, TX, 2024 - Present

Professor, The University of Texas MD Anderson Cancer Center, Houston, TX, 2021 - 2025

Industry Advisory Board Member, University of Houston, Houston, Texas, 2020 - Present

Associate Professor, The University of Texas MD Anderson Cancer Center, Houston, TX, 2018 - 2021

Assistant Professor, The University of Texas MD Anderson Cancer Center ~ Department of Leukemia, Houston, TX, 2010 - 2018

Co-Director, Flow Cytometry & Cell Imaging Core Facility, The University of Texas MD Anderson Cancer Center, Houston, TX, 2010 - 2025

Research Scientist, Department of Stem Cell Transplantation, The University of Texas MD Anderson Cancer Center, Houston, TX, 2007 - 2010

Postdoctoral Associate, Baylor College of Medicine - Division of Cardiothoracic Surgery - Michael DeBakey Department of Surgery, Houston, TX, 2006 - 2007

Research Assistant, The Max D. Summers Laboratory, Department of Entomology, College Station, TX, 1995 - 1998

Necropsy Assistant, Arkansas Livestock and Poultry Pathology Laboratory, Little Rock, AR, 1993

Laboratory Assistant, Medical Genetics Laboratory, Department of Biology, Melbourne, FL, 1990 - 1994

Institutional Committee Activities

Member, CCSG Executive Committee, 2025 - Present

Member, Digital Pathology Workforce, 2020 - Present

Member, Alternate Technologies for COVID Task Force, 2020

Member, TMC3 Science Think Tank, 2020

Member, Basic Science/Laboratory Research Recovery Plan Committee, 2020 - 2020

Member, DIY PPE Task Force, 2020 - 2020

Member, Research Storage Planning & Governance Committee, 2014 - Present

Member, SharePoint Advisory Team, 2013 - 2015

Member, Research IT Steering Committee, 2012 - 2013

Honors & Awards

2004	American Society of Virology, 2004 Annual Meeting, McGill University, Montreal, Canada
2003	Entomology Graduate Student Forum Presentation Award, Texas A&M University

Professional Memberships

American Association for Cancer Research

2024 - Present

American Society for Mass Spectrometry

2023 - Present

Society for Immunotherapy of Cancer

2022 - Present

Digital Pathology Association

2020 - Present

Association of Biomolecular Resource Facilities

2017 - Present

International Society for Advancement of Cytometry

2013 - Present

Texas A&M University Light Microscopy Users Group

2002 - 2004

American Society of Virology

2000 - 2005

American Society of Microbiology

1998 - 2003

Selected Publications

Peer-Reviewed Articles

Liu Y, Sinjab A, Min J, Han G, Paradiso F, Zhang Y, Wang R, Pei G, Dai Y, Liu Y, Cho KS, Dai E, Basi A, Burks JK, Rajapakshe KI, Chu Y, Jiang J, Zhang D, Yan X, Guerrero PA, Serrano A, Li M, Hwang TH, Futreal A, Ajani JA, Solis Soto LM, Jazaeri AA, Kadara H, Maitra A, Wang L. Conserved spatial subtypes and cellular neighborhoods of cancer-associated fibroblasts revealed by single-cell spatial multi-omics. Cancer Cell 43(5):905-924.e6, 2025. e-Pub 2025. PMID: 40154487.
Casso-Chapa B, Vazquez Gonzalez NA, Le NT, Palaskas NL, Nead KT, Eutsey LP, Samanthapudi VSK, Osborn AM, Lee J, Mejia G, Hoang O, Lin SH, Deswal A, Herrmann J, Wang G, Kirkland JL, Krishnan S, Wehrens XHT, Chini EN, Yusuf SW, Iliescu CA, Jain A, Burks JK, Seeley E, Lorenzi PL, Chau KM, Ostos-Mendoza KC, Grumbach IM, Brookes PS, Hanssen NMJ, de Winther MPJ, Yvan-Charvet L, Kotla S, Schadler K, Abe JI. Reevaluating Anti-Inflammatory Therapy: Targeting Senescence to Balance Anti-Cancer Efficacy and Vascular Disease. Arterioscler Thromb Vasc Biol 45(3):372-385, 2025. e-Pub 2025. PMID: 39817327.
Najem H, Pacheco S, Turunen J, Tripathi S, Steffens A, McCortney K, Walshon J, Chandler J, Stupp R, Lesniak MS, Horbinski CM, Winkowski D, Kowal J, Burks JK, Heimberger AB. High Dimensional Proteomic Multiplex Imaging of the Central Nervous System Using the COMET() System. bioRxiv, 2025. e-Pub 2025. PMID: 40027731.
Eliason, J, Krishnan, S, Fukuda, Y, Bustos, M, Winkowski, D, Cho, SN, Basi, A, Baird, R, Grimm, EA, Davies, MA, Hoon, DS, Uppore Kukkillaya, AR, Burks, JK, Ekmekcioglu, S. Characterizing spatial immune architecture in metastatic melanoma using high-dimensional multiplex imaging. Frontiers in immunology 16, 2025. e-Pub 2025. PMID: 40364843.
Carstens, JL, Krishnan, S, Uppore Kukkillaya, AR, Sorace, AG, Seeley, EH, Ferri-Borgogno, S, Burks, JK. Spatial multiplexing and omics. Nature Reviews Methods Primers 4(1), 2024. e-Pub 2024.
Sainz, TP, Sahu, V, Gomez, JA, Dcunha, NJ, Basi, A, Kettlun, C, Sarami, I, Burks, JK, Sampath, D, Vega Vazquez, F. Role of the Crosstalk B:Neoplastic T Follicular Helper Cells in the Pathobiology of Nodal T Follicular Helper Cell Lymphomas. Laboratory Investigation 104(11), 2024. e-Pub 2024. PMID: 39389311.
Marques-Piubelli ML, Kumar B, Basar R, Panowski S, Srinivasan S, Norwood K, Prashad S, Szenes V, Balakumaran A, Arandhya A, Lu W, Khan K, Duenas D, McAllen S, Gomez JA, JK B, Acharyal S, Borthakur G, Wang WL, Wang W, Wang S, Solis LM, Mari D, Rezvani K, Daher M, Fn V. Increased Expression of CD70 in Relapsed Acute Myeloid Leukemia after Hypomethylating Agents. Virchows Arch 485(5):937-941, 2024. e-Pub 2024. PMID: 38388965.
Maksimovic, S, Boscolo, NC, La Posta, L, Barrios, S, Moussa, MJ, Gentile, E, Pesquera, P, Li, W, Chen, J, Gomez, JA, Basi, A, Burks, JK, Alvarez-Breckenridge, C, Gao, J, Campbell, M, Dondossola, E. Antiangiogenic Tyrosine Kinase Inhibitors have Differential Efficacy in Clear Cell Renal Cell Carcinoma in Bone. Cancer Research Communications 4(10):2621-2637, 2024. e-Pub 2024. PMID: 39248577.
Islam S, Gleber-Netto FO, Mulcahy CF, Glaun MDE, Srivastava S, Hunt PJ, Williams MD, Barbon CE, Spiotto M, Zhao W, Adebayo A, Akhter S, Xie T, Debnath KC, Sathishkumar HN, Myers B, Lothumalla S, Yaman I, JK B, Gomez J, Rao X, Wang J, Woodman K, Mansour J, Arenkiel B, Osman KL, Haxton C, Lever TE, Hutcheson KA, Amit M. Neural landscape is associated with functional outcomes in irradiated patients with oropharyngeal squamous cell carcinoma. Sci Transl Med 16(758):eabq5585, 2024. e-Pub 2024. PMID: 39083586.
Hoke ATK, Takahashi Y, Padget MR, Gomez J, Amit M, JK B, Bell D, Xie T, Soon-Shiong P, Hodge JW, Hanna EY, London NR. Targeting Sinonasal Undifferentiated Carcinoma with a Combinatory Immunotherapy Approach. Transl Oncol 44:101943, 2024. e-Pub 2024. PMID: 38593586.
Najem H, Pacheco S, Kowal J, Winkowski D, JK B, Heimberger AB. Protocol to quantify immune cell distribution from the vasculature to the glioma microenvironment on sequential immunofluorescence multiplex images. STAR Protoc 5(2):103079, 2024. e-Pub 2024. PMID: 38795354.
Wang B, Reville PK, Yassouf MY, Jelloul FZ, Ly C, Desai PN, Wang Z, Borges P, Veletic I, Dasdemir E, JK B, Tang G, Guo S, Garza AI, Nasnas C, Vaughn NR, Baran N, Deng Q, Matthews J, Gunaratne PH, Antunes DA, Ekmekcioglu S, Sasaki K, Garcia MB, Cuglievan B, Hao D, Daver N, Green MR, Konopleva M, Futreal A, Post SM, Abbas HA. Comprehensive Characterization of IFNγ Signaling in Acute Myeloid Leukemia Reveals Prognostic and Therapeutic Strategies. Nat Commun 15(1):1821, 2024. e-Pub 2024. PMID: 38418901.
Ferri-Borgogno S, JK B, Seeley EH, McKee TD, Stolley DL, Basi AV, Gomez JA, Gamal BT, Ayyadhury S, Lawson BC, Yates MS, Birrer MJ, Lu KH, Mok SC. Molecular, Metabolic, and Subcellular Mapping of the Tumor Immune Microenvironment via 3D Targeted and Non-Targeted Multiplex Multi-Omics Analyses. Cancers (Basel) 16(5), 2024. e-Pub 2024. PMID: 38473208.
Saldarriaga, OA, Wanninger, T, Arroyave, E, Gosnell, J, Krishnan, S, Oneka, MD, Bao, D, Millian, DE, Kueht, ML, Moghe, A, Jiao, J, Sanchez, JI, Spratt, HM, Beretta, L, Uppore Kukkillaya, AR, Burks, JK, Stevenson, HL. Heterogeneity in intrahepatic macrophage populations and druggable target expression in patients with steatotic liver disease-related fibrosis. JHEP Reports 6(1), 2024. e-Pub 2024. PMID: 38162144.
Zhao M, Wang T, Gleber-Netto FO, Chen Z, McGrail DJ, Gomez JA, Ju W, Gadhikar MA, Ma W, Shen L, Wang Q, Tang X, Pathak S, Raso MG, JK B, Lin SY, Wang J, Multani AS, Pickering CR, Chen J, Myers JN, Zhou G. Mutant p53 gains oncogenic functions through a chromosomal instability-induced cytosolic DNA response. Nat Commun 15(1):180, 2024. e-Pub 2024. PMID: 38167338.
Saldarriaga OA, Wanninger TG, Arroyave E, Gosnell J, Krishnan S, Oneka M, Bao D, Millian DE, Kueht ML, Moghe A, Jiao J, Sanchez JI, Spratt H, Beretta L, Rao A, JK B, Stevenson HL. Heterogeneity in intrahepatic macrophage populations and druggable target expression in patients with steatotic liver disease-related fibrosis. JHEP 6(1), 2024. e-Pub 2024.
Zhang J, Dai H, Huo L, JK B, McGrail DJ, Lin SY. Cytosolic DNA accumulation promotes breast cancer immunogenicity via a STING-independent pathway. J Immunother Cancer 11(10), 2023. e-Pub 2023. PMID: 37907220.
Sans M, Makino Y, Min J, Rajapakshe KI, Yip-Schneider M, Schmidt CM, Hurd MW, JK B, Gomez JA, Thege FI, Fahrmann JF, Wolff RA, Kim MP, Guerrero PA, Maitra A. Spatial Transcriptomics of Intraductal Papillary Mucinous Neoplasms of The Pancreas Identifies NKX6-2 as a Driver of Gastric Differentiation and Indolent Biological Potential. Cancer Discov 13(8):1844-1861, 2023. e-Pub 2023. PMID: 37285225.
Sousa LG, McGrail DJ, Lazar Neto F, Li K, Marques-Piubelli ML, Ferri-Borgogno S, Dai H, Mitani Y, Spardy Burr N, Cooper ZA, Kinneer K, Cortez MA, Lin SY, Bell D, El Naggar A, JK B, Ferrarotto R. Spatial Immunoprofiling of Adenoid Cystic Carcinoma Reveals B7-H4 Is a Therapeutic Target for Aggressive Tumors. Clin Cancer Res 29(16):3162-3171, 2023. e-Pub 2023. PMID: 37256648.
Desai PN, Wang B, Fonseca A, Borges P, Jelloul FZ, Reville PK, Lee E, Ly C, Basi A, Root J, Baran N, Post SM, Deng Q, Sun H, Harmanci AO, JK B, Gomez JA, DiNardo CD, Daver NG, Alatrash G, Konopleva M, Green MR, Antunes DA, Futreal A, Hao D, Abbas HA. Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion. Cancer Immunol Res 11(7):1011-1028, 2023. e-Pub 2023. PMID: 37163233.
Baruch EN, Nagarajan P, Gleber-Netto FO, Rao X, Xie T, Akhter S, Adewale A, Shajedul I, Mattson BJ, Ferrarotto R, Wong MK, Davies MA, Jindal S, Basu S, Harwood C, Leigh I, Ajami N, Futreal A, Castillo M, Gunaratne P, Goepfert RP, Khushalani N, Wang J, Watowich S, Calin GA, Migden MR, Vermeer P, D'Silva N, Yaniv D, JK B, Gomez J, Dougherty PM, Tsai KY, Allison JP, Sharma P, Wargo J, Myers JN, Gross ND, Amit M. Inflammation induced by tumor-associated nerves promotes resistance to anti-PD-1 therapy in cancer patients and is targetable by interleukin-6 blockade. Res Sq, 2023. e-Pub 2023. PMID: 37503252.
Fukuda Y, Kim SH, Bustos MA, Cho SN, Roszik J, JK B, Kim H, Hoon DSB, Grimm EA, Ekmekcioglu S. Inhibition of Microsomal Prostaglandin E2 Synthase Reduces Collagen Deposition in Melanoma Tumors and May Improve Immunotherapy Efficacy by Reducing T-cell Exhaustion. Cancer Res Commun 3(7):1397-1408, 2023. e-Pub 2023. PMID: 37529399.
Pourebrahim R, Heinz Montoya R, Alaniz Z, Ostermann L, Lin PP, Liu B, Ayoub E, JK B, Andreeff M. Mdm2/p53 levels in bone marrow mesenchymal stromal cells are essential for maintaining the hematopoietic niche in response to DNA damage. Cell Death Dis 14(6):371, 2023. e-Pub 2023. PMID: 37353528.
Jia Y, Zhang W, Basyal M, Chang KH, Ostermann L, JK B, Ly C, Mu-Mosley H, Zhang Q, Han X, Fogler WE, Magnani JL, Lesegretain A, Zal AA, Zal T, Andreeff M. FLT3 inhibitors upregulate CXCR4 and E-selectin ligands via ERK suppression in AML cells and CXCR4/E-selectin inhibition enhances anti-leukemia efficacy of FLT3-targeted therapy in AML. Leukemia 37(6):1379-1383, 2023. e-Pub 2023. PMID: 37085610.
Abe JI, Imanishi M, Li S, Zhang A, Ko KA, Samanthapudi VSK, Lee LL, Bojorges AP, Gi YJ, Hobbs BP, Deswal A, Herrmann J, Lin SH, Chini EN, Shen YH, Schadler KL, Nguyen TH, Gupte AA, Reyes-Gibby C, Yeung SJ, Abe RJ, Olmsted-Davis EA, Krishnan S, Dantzer R, Palaskas NL, Cooke JP, Pownall HJ, Yoshimoto M, Fujiwara K, Hamilton DJ, JK B, Wang G, Le NT, Kotla S. An ERK5-NRF2 Axis Mediates Senescence-Associated Stemness and Atherosclerosis. Circ Res 133(1):25-44, 2023. e-Pub 2023. PMID: 37264926.
Desai PN, Wang B, Fonseca A, Borges P, Jelloul FZ, Reville PK, Lee E, Ly C, Basi A, Root J, Baran N, Post SM, Deng Q, Sun H, Harmanci AO, JK B, Gomez JA, DiNardo CD, Daver NG, Alatrash G, Konopleva M, Green MR, Antunes DA, Futreal A, Hao D, Abbas HA. Single-cell Profiling of CD8 T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion. Cancer Immunol Res:OF1-OF18. e-Pub 2023. PMID: 37285177.
Ferri-Borgogno S, Zhu Y, Sheng J, JK B, Gomez JA, Wong KK, Wong STC, Mok SC. Spatial transcriptomics depict ligand-receptor crosstalk heterogeneity at the tumor-stroma interface in long-term ovarian cancer survivors. Cancer Res 83(9):1503-1516, 2023. e-Pub 2023. PMID: 36787106.
Pourebrahim R, Montoya RH, Alaniz Z, Ostermann L, Lin PP, Liu B, Ayoub E, Burks JK, Andreeff M. Mdm2/p53 levels in bone marrow mesenchymal stromal cells is essential for maintaining the hematopoietic niche in response to DNA damage. Res Sq, 2023. e-Pub 2023. PMID: 36909480.
Fukuda Y, Kim S, Bustos M, Cho S, Roszik J, Burks JK, Kim H, Hoon D, Grimm E, Ekmekcioglu AS. Inhibition of microsomal prostaglandin E2 synthase has a potential to improve immunotherapy by reducing collagen deposition and T cell exhaustion in melanoma. Cancer Research Communications 3(7):1397-1408, 2023. e-Pub 2023. PMID: 37529399.
Wang X, Semba T, Manyam GC, Wang J, Shao S, Bertucci F, Finetti P, Krishnamurthy S, Phi LTH, Pearson T, Van Laere SJ, Burks JK, Cohen EN, Reuben JM, Yang F, Min H, Navin N, Trinh VN, Iwase T, Batra H, Shen Y, Zhang X, Tripathy D, Ueno NT. EGFR is a master switch between immunosuppressive and immunoactive tumor microenvironment in inflammatory breast cancer. Sci Adv 8(50):eabn7983, 2022. e-Pub 2022. PMID: 36525493.
Kang Y, Deng J, Ling J, Li X, Chiang YJ, Koay EJ, Wang H, Burks JK, Chiao PJ, Hurd MW, Bhutani MS, Lee JH, Weston BR, Maitra A, Ikoma N, Tzeng CD, Lee JE, DePinho RA, Wolff RA, Pant S, McAllister F, Katz MH, Fleming JB, Kim MP. 3D imaging analysis on an organoid-based platform guides personalized treatment in pancreatic ductal adenocarcinoma. J Clin Invest 132(24), 2022. e-Pub 2022. PMID: 36282600.
Radnaa E, Richardson L, Goldman B, Burks JK, Baljinnyam T, Vora N, Zhang HJ, Bonney EA, Han A, Menon R. Stress Signaler p38 Mitogen-Activated Kinase Activation: A Cause for Concern?. Clin Sci (Lond) 136(22):1591-1614, 2022. e-Pub 2022. PMID: 36250628.
Amit M, Xie T, Gleber-Netto FO, Hunt PJ, Mehta GU, Bell D, Silverman DA, Yaman I, Ye Y, Burks JK, Fuller GN, Gidley PW, Nader ME, Raza SM, DeMonte F. Distinct immune signature predicts progression of vestibular schwannoma and unveils a possible viral etiology. J Exp Clin Cancer Res 41(1):292, 2022. e-Pub 2022. PMID: 36195959.
Li H, Wang Y, Lin K, Venkadakrishnan VB, Bakht M, Shi W, Meng C, Zhang J, Tremble K, Liang X, Song JH, Feng X, Van V, Deng P, Burks JK, Aparicio A, Keyomarsi K, Chen J, Lu Y, Beltran H, Zhao D. CHD1 Promotes Sensitivity to Aurora Kinase Inhibitors by Suppressing Interaction of AURKA with Its Coactivator TPX2. Cancer Res 82(17):3088-3101, 2022. e-Pub 2022. PMID: 35771632.
Hailemichael, Y, Johnson, DH, Hassan, NA, Foo, WC, Bentebibel, SE, Daher, M, Haymaker, CL, Wani, K, Saberian, C, Ogata, D, Kim, ST, Nurieva, R, Lazar, A, Abu-Sbeih, H, Fa'Ak, F, Mathew, A, Wang, Y, Falohun, A, Trinh, VA, Zobniw, C, Spillson, C, Burks, JK, Awiwi, M, Elsayes, KM, Solis Soto, LM, Melendez, B, Davies, MA, Wargo, J, Curry, JL, Yee, C, Lizee, GA, Singh, S, Sharma, P, Allison, JP, Hwu, P, Ekmekcioglu, S, Diab, A. Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer cell 40(5):509-523.e6, 2022. e-Pub 2022. PMID: 35537412.
Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Daher M, Haymaker C, Wani KM, Saberian CM, Ogata D, Bentebibel SE, Kim ST, Nurieva R, Lazar A, Abu-Sbeih H, Wang Y, Trinh VA, Zobniw CM, Spillson CA, Burks JK, Solis L, Cruz AF, Marques-Piubelli ML, Lu W, Melendez BD, Davies MA, Wargo J, Curry JL, Lizee GA, Yee C, Hwu P, Ekmekcioglu S, Diab A. Interleukin-6 blockade abrogates CTLA-4 blockade immune toxicity and promotes antitumor immunity. Cancer Cell 40(5):509-523. e6. e-Pub 2022.
Fukuda Y, Bustos MA, Cho SN, Roszik J, Ryu S, Lopez VM, JK B, Lee JE, Grimm EA, Hoon DSB, Ekmekcioglu S. Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma. Cell Death Dis 13(5):422, 2022. e-Pub 2022. PMID: 35501311.
Najem H, Ott M, Kassab C, Rao A, Rao G, Marisetty A, Sonabend AM, Horbinski C, Verhaak R, Shankar A, Krishnan SN, Varn FS, Arrieta VA, Gupta P, Ferguson SD, Huse JT, Fuller GN, Long JP, Winkowski DE, Freiberg BA, James CD, Platanias LC, Lesniak MS, Burks JK, Heimberger AB. Central nervous system immune interactome is function of cancer lineage, tumor microenvironment and STAT3 expression. JCI Insight 7(9), 2022. e-Pub 2022. PMID: 35316217.
Millian DE, Saldarriaga OA, Wanninger T, Burks JK, Rafati YN, Gosnell J, Stevenson HL. Cutting-Edge Platforms for Analysis of Immune Cells in the Hepatic Microenvironment-Focus on Tumor-Associated Macrophages in Hepatocellular Carcinoma. Cancers (Basel) 14(8), 2022. e-Pub 2022. PMID: 35454766.
Arrieta VA, Chen AX, Kane JR, Kang SJ, Kassab C, Dmello C, Zhao J, Burdett KB, Upadhyayula PS, Lee-Chang C, Shilati J, Jaishankar D, Chen L, Gould A, Zhang D, Yuan J, Zhao W, Ling X, JK B, Laffleur B, Amidei C, Bruce JN, Lukas RV, Yamaguchi JT, Cieremans D, Rothschild G, Basu U, McCord M, Brat DJ, Zhang H, Cooper LAD, Zhang B, Sims P, Cloughesy TF, Prins R, Canoll P, Stupp R, Heimberger AB, Horbinski C, Iwamoto FM, Rabadan R, Sonabend AM. ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nat Cancer 3(3):373, 2022. e-Pub 2022. PMID: 35149861.
Sousa LG, McGrail DJ, Li K, Marques-Piubelli ML, Gonzalez C, Dai H, Ferri-Borgogno S, Godoy M, Burks JK, Lin SY, Bell D, Ferrarotto R. Spontaneous tumor regression following COVID-19 vaccination. J Immunother Cancer 10(3), 2022. e-Pub 2022. PMID: 35241495.
Fukuda Y, Bustos MA, Cho SN, Roszik J, Ryu S, Lopez VM, JK B, Lee JE, Grimm EA, Hoon DSB, Ekmekcioglu S. Interplay between soluble CD74 and macrophage-migration inhibitory factor drives tumor growth and influences patient survival in melanoma. Cell Death Dis 13(2):117, 2022. e-Pub 2022. PMID: 35121729.
Quesada PR, Riquelme E, Burks JK, Rakoski A, Sahin I, McAllister F. Assessment of the Murine Tumor Microenvironment by Multiplex Immunofluorescence. Methods Mol Biol 2435:107-127, 2022. e-Pub 2022. PMID: 34993942.
Imanishi M, Cheng H, Kotla S, Deswal A, Le NT, Chini E, Ko KA, Samanthapudi VSK, Lee LL, Herrmann J, Xu X, Reyes-Gibby C, Yeung SJ, Schadler KL, Yusuf SW, Liao Z, Nurieva R, Amir ED, Burks JK, Palaskas NL, Cooke JP, Lin SH, Kobayashi M, Yoshimoto M, Abe JI. Radiation therapy induces immunosenescence mediated by p90RSK. Front Cardiovasc Med 9:988713, 2022. e-Pub 2022. PMID: 36426217.
Corvigno S, Burks JK, Hu W, Zhong Y, Jennings NB, Fleming ND, Westin SN, Fellman B, Liu J, Sood AK. Immune microenvironment composition in high-grade serous ovarian cancers based on BRCA mutational status. J Cancer Res Clin Oncol 147(12):3545-3555, 2021. e-Pub 2021. PMID: 34476576.
Arrieta VA, Chen AX, Kane JR, Kang SJ, Kassab C, Dmello C, Zhao J, Burdett KB, Upadhyayula PS, Lee-Chang C, Shilati J, Jaishankar D, Chen L, Gould A, Zhang D, Yuan J, Zhao W, Ling X, Burks JK, Laffleur B, Amidei C, Bruce JN, Lukas RV, Yamaguchi JT, Cieremans D, Rothschild G, Basu U, McCord M, Brat DJ, Zhang H, Cooper LAD, Zhang B, Sims P, Cloughesy TF, Prins R, Canoll P, Stupp R, Heimberger AB, Horbinski C, Iwamoto FM, Rabadan R, Sonabend AM. ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nat Cancer 2(12):1372-1386, 2021. e-Pub 2021. PMID: 35121903.
Kotla S, Zhang A, Imanishi M, Ko KA, Lin SH, Gi YJ, Moczygemba M, Isgandarova S, Schadler KL, Chung C, Milgrom SA, Banchs J, Yusuf SW, Amaya DN, Guo H, Thomas TN, Shen YH, Deswal A, Herrmann J, Kleinerman ES, Entman ML, Cooke JP, Schifitto G, Maggirwar SB, McBeath E, Gupte AA, Krishnan S, Patel ZS, Yoon Y, Burks JK, Fujiwara K, Brookes PS, Le NT, Hamilton DJ, Abe JI. Nucleus-mitochondria positive feedback loop formed by ERK5 S496 phosphorylation-mediated poly (ADP-ribose) polymerase activation provokes persistent pro-inflammatory senescent phenotype and accelerates coronary atherosclerosis after chemo- radiation. Redox Biol 7:102132, 2021. e-Pub 2021. PMID: 34619528.
Muftuoglu M, Li L, Liang S, Mak D, Lin AJ, Fang J, Burks JK, Chen K, Andreeff M. Extended Live-cell Barcoding Approach for Multiplexed Mass Cytometry. Sci Rep 11(1):12388, 2021. e-Pub 2021. PMID: 34117319.
Bommi PV, Bowen CM, Reyes-Uribe L, Wu W, Katayama H, Rocha P, Parra ER, Francisco-Cruz A, Ozcan Z, Tosti E, Willis JA, Wu H, Taggart MW, Burks JK, Lynch PM, Edelmann W, Scheet PA, Wistuba II, Sinha KM, Hanash SM, Vilar E. The Transcriptomic Landscape of Mismatch Repair-Deficient Intestinal Stem Cells. Cancer Res 81(10):2760-2773, 2021. e-Pub 2021. PMID: 34003775.
Zhu Y, Ferri-Borgogno S, Sheng J, Yeung TL, Burks JK, Cappello P, Jazaeri AA, Kim JH, Han GH, Birrer MJ, Mok SC, Wong STC. SIO: A Spatioimageomics Pipeline to Identify Prognostic Biomarkers Associated with the Ovarian Tumor Microenvironment. Cancers (Basel) 13(8), 2021. e-Pub 2021. PMID: 33917869.
Carstens JL, Yang S, Correa de Sampaio P, Zheng X, Barua S, McAndrews KM, Rao A, Burks JK, Rhim AD, Kalluri R. Stabilized Epithelial Phenotype of Cancer Cells in Primary Tumors Leads to Increased Colonization of Liver Metastasis in Pancreatic Cancer. Cell Rep 35(2):108990, 2021. e-Pub 2021. PMID: 33852841.
Sarkar A, Stellrecht CM, Vangapandu HV, Ayres M, Kaipparettu BA, Park JH, Balakrishnan K, Burks JK, Pandita TK, Hittelman WN, Neelapu SS, Gandhi V. Ataxia telangiectasia mutated interacts with Parkin and induces mitophagy independent of kinase activity. Evidence from mantle cell lymphoma. Haematologica 106(2):495-512, 2021. e-Pub 2021. PMID: 32029507.
Najem H, Marisetty A, Horbinski C, Long J, Huse JT, Glitza Oliva IC, Ferguson SD, Kumthekar PU, Wainwright DA, Chen P, Lesniak MS, Burks JK, Heimberger AB. CD11c+CD163+ Cells and Signal Transducer and Activator of Transcription 3 (STAT3) Expression Are Common in Melanoma Leptomeningeal Disease. Frontiers in immunology 12:4209, 2021. e-Pub 2021. PMID: 34691054.
Chen B, Dragomir MP, Fabris L, Bayraktar R, Knutsen E, Liu X, Tang C, Li Y, Shimura T, Ivkovic TC, Cruz De Los Santos M, Anfossi S, Shimizu M, Shah MY, Ling H, Shen P, Multani AS, Pardini B, Burks JK, Katayama H, Reineke LC, Huo L, Syed M, Song S, Ferracin M, Oki E, Fromm B, Ivan C, Bhuvaneshwar K, Gusev Y, Mimori K, Menter D, Sen S, Matsuyama T, Uetake H, Vasilescu C, Kopetz S, Parker-Thornburg J, Taguchi A, Hanash SM, Girnita L, Slaby O, Goel A, Varani G, Gagea M, Li C, Ajani JA, Calin GA. The Long Noncoding RNA CCAT2 induces chromosomal instability through BOP1 - AURKB signaling. Gastroenterology 159(6):2146-2162.e33, 2020. e-Pub 2020. PMID: 32805281.
Zhang Y, Chandra V, Riquelme Sanchez E, Dutta P, Quesada PR, Rakoski A, Zoltan M, Arora N, Baydogan S, Horne W, Burks JK, Xu H, Hussain P, Wang H, Gupta S, Maitra A, Bailey JM, Moghaddam SJ, Banerjee S, Sahin I, Bhattacharya P, McAllister F. Interleukin 17 induced- neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer. J Exp Med 217(12), 2020. e-Pub 2020. PMID: 32860704.
Ott M, Kassab C, Marisetty A, Hashimoto Y, Wei J, Zamler D, Leu JS, Tomaszowski KH, Sabbagh A, Fang D, Gupta P, Priebe W, Zielinski RJ, Burks JK, Long JP, Kong LY, Fuller GN, DeGroot J, Sulman EP, Heimberger AB. Radiation with STAT3 blockade triggers dendritic cell-T cell interactions in the glioma microenvironment and therapeutic efficacy. Clin Cancer Res 26(18):4983-4994, 2020. e-Pub 2020. PMID: 32605912.
Batth IS, Meng Q, Wang Q, Torres KE, Burks JK, Wang J, Gorlick R, Li S. Rare osteosarcoma cell subpopulation protein array and profiling using imaging mass cytometry and bioinformatics analysis. BMC Cancer 20(1):715, 2020. e-Pub 2020. PMID: 32736533.
Saldarriaga OA, Freiberg B, Krishnan S, Rao A, Burks JK, Booth AL, Dye B, Utay N, Ferguson M, Akil A, Yi M, Beretta L, Stevenson HL. Multispectral Imaging Enables Characterization of Intrahepatic Macrophages in Patients With Chronic Liver Disease. Hepatol Commun 4(5):708-723, 2020. e-Pub 2020. PMID: 32363321.
Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Celestino J, Morgan MB, Nguyen TV, Conrads KA, Rangel KM, Dood RL, Hajek RA, Fawcett GL, Chu RA, Wilson K, Loffredo JL, Viollet C, Jazaeri AA, Dalgard CL, Mao X, Song X, Zhou M, Hood BL, Banskota N, Wilkerson MD, Te J, Soltis AR, Roman K, Dunn A, Cordover D, Eterovic AK, Liu J, Burks JK, Baggerly KA, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Casablanca Y, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. Molecular analysis of clinically defined subsets of high-grade serous ovarian cancer. Cell Rep 31(2):107502, 2020. e-Pub 2020. PMID: 32294438.
Han L, Zhang Q, Dail M, Shi C, Cavazos A, Ruvolo VR, Zhao Y, Kim E, Rahmani M, Mak DH, Jin SS, Chen J, Phillips DC, Koller PB, Jacamo R, Burks JK, DiNardo C, Daver N, Jabbour E, Wang J, Kantarjian HM, Andreeff M, Grant S, Leverson JD, Sampath D, Konopleva M. Concomitant targeting of BCL2 with venetoclax and MAPK signaling with cobimetinib in acute myeloid leukemia models. Haematologica 105(3):697-707, 2020. e-Pub 2020. PMID: 31123034.
Burks JK. Going Beyond Sight, Revealing Multiplex Biology. Journal of Pathology Informatics, 2020. e-Pub 2020.
Lara OD, Krishnan S, Wang Z, Corvigno S, Zhong Y, Lyons Y, Dood R, Hu W, Qi L, Liu J, Coleman RL, Westin SN, Fleming ND, Cristini V, Rao A, Burks JK, Sood AK. Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma. Sci Rep 9(1):17589, 2019. e-Pub 2019. PMID: 31772388.
Yokoi A, Villar-Prados A, Oliphint PA, Zhang J, Song X, De Hoff P, Morey R, Liu J, Roszik J, Clise-Dwyer K, Burks JK, O'Halloran TJ, Laurent LC, Sood AK. Mechanisms of nuclear content loading to exosomes. Sci Adv 5(11):eaax8849, 2019. e-Pub 2019. PMID: 31799396.
Chattopadhyay C, Oba J, Roszik J, Marszalek JR, Chen K, Qi Y, Eterovic K, Robertson AG, Burks JK, McCannel TA, Grimm EA, Woodman SE. Elevated Endogenous SDHA Drives Pathological Metabolism in Highly Metastatic Uveal Melanoma. Invest Ophthalmol Vis Sci 60(13):4187-4195, 2019. e-Pub 2019. PMID: 31596927.
Kannan S, Aitken MJL, Herbrich SM, Golfman LS, Hall MG, Mak DH, Burks JK, Song G, Konopleva M, Mullighan CG, Chandra J, Zweidler-McKay PA. Anti-Leukemia Effects of Notch-Mediated Inhibition of Oncogenic PLK1 in B-Cell Acute Lymphoblastic Leukemia. Mol Cancer Ther 18(9):1615-1627, 2019. e-Pub 2019. PMID: 31227645.
Riquelme E, Zhang Y, Zhang L, Montiel M, Zoltan M, Dong W, Quesada P, Sahin I, Chandra V, San Lucas A, Scheet P, Xu H, Hanash SM, Feng L, Burks JK, Do KA, Peterson CB, Nejman D, Tzeng CD, Kim MP, Sears CL, Ajami N, Petrosino J, Wood LD, Maitra A, Straussman R, Katz M, White JR, Jenq R, Wargo J, McAllister F. Tumor Microbiome Diversity and Composition Influence Pancreatic Cancer Outcomes. Cell 178(4):795-806.e12, 2019. e-Pub 2019. PMID: 31398337.
Carter BZ, Mak PY, Wang X, Tao W, Ruvolo V, Mak D, Mu H, Burks JK, Andreeff M. An ARC-regulated IL1β/Cox-2/PGE2/β-catenin/ARC circuit controls leukemia-microenvironment interactions and confers drug resistance in AML. Cancer Res 79(6):1165-1177, 2019. e-Pub 2019. PMID: 30674535.
Dharmaraj N, Piotrowski SL, Huang C, Newton JM, Golfman LS, Hanoteau A, Koshy ST, Li AW, Pulikkathara MX, Zhang B, Burks JK, Mooney DJ, Lei YL, Sikora AG, Young S. Anti-tumor immunity induced by ectopic expression of viral antigens is transient and limited by immune escape. Oncoimmunology 8(4):e1568809, 2019. e-Pub 2019. PMID: 30906661.
Kassab C, Levine J, Boudreau B, Ling X, Burks JK, Zhou S, Verhaak R, Heimberger A. IMMU-36. IMMUNE RESPONSES IN CANINE GLIOMAS ARE ENRICHED AT THE INFILTRATING EDGE OF ASTROCYTOMAS. Neuro-oncology 20, 2018. e-Pub 2018.
Reddy JP, Atkinson RL, Larson R, Burks JK, Smith D, Debeb BG, Ruffell B, Creighton CJ, Bambhroliya A, Reuben JM, Van Laere SJ, Krishnamurthy S, Symmans WF, Brewster AM, Woodward WA. Mammary stem cell and macrophage markers are enriched in normal tissue adjacent to inflammatory breast cancer. Breast Cancer Res Treat 171(2):283-293, 2018. e-Pub 2018. PMID: 29858753.
Ruvolo PP, Ruvolo VR, Burks JK, Qiu Y, Wang RY, Shpall EJ, Mirandola L, Hail N, Zeng Z, McQueen T, Daver N, Post SM, Chiriva-Internati M, Kornblau SM, Andreeff M. Role of MSC-derived galectin 3 in the AML microenvironment. Biochim Biophys Acta Mol Cell Res 1865(7):959-969, 2018. e-Pub 2018. PMID: 29655803.
Jiang X, Mak PY, Mu H, Tao W, Mak DH, Kornblau S, Zhang Q, Ruvolo P, Burks JK, Zhang W, McQueen T, Pan R, Zhou H, Konopleva M, Cortes J, Liu Q, Andreeff M, Carter BZ. Disruption of Wnt/β-Catenin Exerts Antileukemia Activity and Synergizes with FLT3 Inhibition inFLT3-Mutant Acute Myeloid Leukemia. Clin Cancer Res 24(10):2417-2429, 2018. e-Pub 2018. PMID: 29463558.
ten Hacken E, Gounari M, Back JW, Shimanovskaya E, Scarfò L, Kim E, Burks JK, Ponzoni M, Ramirez GA, Wierda WG, Estrov Z, Keating MJ, Ferrajoli A, Stamatopoulos K, Ghia P, Burger JA. Calreticulin as a novel B-cell receptor antigen in chronic lymphocytic leukemia. Haematologica 102(10):e394-e396, 2017. e-Pub 2017. PMID: 28751563.
McCarthy RL, Mak DH, Burks JK, Barton MC. Rapid monoisotopic cisplatin based barcoding for multiplexed mass cytometry. Sci Rep 7(1):3779, 2017. e-Pub 2017. PMID: 28630464.
Liu S, Anfossi S, Qiu B, Zheng Y, Cai M, Fu J, Yang H, Liu Q, Chen Z, Fu J, Liu M, Burks JK, Lin SH, Reuben J, Liu H. Prognostic Factors for Locoregional Recurrence in Patients with Thoracic Esophageal Squamous Cell Carcinoma Treated with Radical Two-Field Lymph Node Dissection: Results from Long-Term Follow-Up. Ann Surg Oncol 24(4):966-973, 2017. e-Pub 2017. PMID: 27804027.
Jang HJ, Lee HS, Burt BM, Lee GK, Yoon KA, Park YY, Sohn BH, Kim SB, Kim MS, Lee JM, Joo J, Kim SC, Yun JS, Na KJ, Choi YL, Park JL, Kim SY, Lee YS, Han L, Liang H, Mak D, Burks JK, Zo JI, Sugarbaker DJ, Shim YM, Lee JS. Integrated Genomic Analysis of Recurrence-Associated Small Non-coding RNAs in Oesophageal Cancer. Gut 66(2):215-225, 2017. e-Pub 2017. PMID: 27507904.
Mansfield JR, Guest PC, Burks JK. Phenotyping Multiple Subsets of Immune Cells In Situ in Formalin-Fixed, Paraffin-Embedded Tissue Sections. Adv Exp Med Biol 974:327-338, 2017. e-Pub 2017. PMID: 28353253.
Ruvolo PP, Ruvolo VR, Benton CB, AlRawi A, Burks JK, Schober W, Rolke J, Tidmarsh G, Hail N, Davis RE, Andreeff M. Combination of galectin inhibitor GCS-100 and BH3 mimetics eliminates both p53 wild type and p53 null AML cells. Biochim Biophys Acta 1863(4):562-71, 2016. e-Pub 2016. PMID: 26704388.
Carter BZ, Mak PY, Chen Y, Mak DH, Mu H, Jacamo R, Ruvolo V, Arold ST, Ladbury JE, Burks JK, Kornblau S, Andreeff M. Anti-apoptotic ARC protein confers chemoresistance by controlling leukemia-microenvironment interactions through a NFκB/IL1β signaling network. Oncotarget 7(15):20054-67, 2016. e-Pub 2016. PMID: 26956049.
Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, Burks JK, Fuller GN, Calin GA, Conrad CA, Creasy C, Ritthipichai K, Radvanyi L, Heimberger AB. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol 18(2):195-205, 2016. e-Pub 2016. PMID: 26323609.
Han L, Qiu P, Zeng Z, Jorgensen JL, Mak DH, Burks JK, Schober W, McQueen TJ, Cortes J, Tanner SD, Roboz GJ, Kantarjian HM, Kornblau SM, Guzman ML, Andreeff M, Konopleva M. Single-cell mass cytometry reveals intracellular survival/proliferative signaling in FLT3-ITD-mutated AML stem/progenitor cells. Cytometry A 87(4):346-56, 2015. e-Pub 2015. PMID: 25598437.
Ruvolo PP, Ruvolo VR, Benton C, Burks JK, Schober W, Rolke J, Tidmarsh G, Hail N, Davis E, Andreeff M. Galectin inhibitor GCS-100 synergizes with BH3 mimetics to eliminate AML cells and sensitizes AML cells to KPT-185 be a mechanism involving suppression of XPO1. Biochim Biophys Acta, 2015. e-Pub 2015.
Zhang Y, Nowicka A, Solley TN, Wei C, Parikh A, Court L, Burks JK, Andreeff M, Woodward WA, Dadbin A, Kolonin MG, Lu KH, Klopp AH. Stromal Cells Derived from Visceral and Obese Adipose Tissue Promote Growth of Ovarian Cancers. PLoS One 10(8):e0136361, 2015. e-Pub 2015. PMID: 26317219.
Borthakur G, Duvvuri S, Ruvolo V, Tripathi DN, Piya S, Burks JK, Jacamo R, Kojima K, Ruvolo P, Fueyo-Margareto J, Konopleva M, Andreeff M. MDM2 Inhibitor, Nutlin 3a, Induces p53 Dependent Autophagy in Acute Leukemia by AMP Kinase Activation. PLoS One 10(10):e0139254, 2015. e-Pub 2015. PMID: 26440941.
Ruvolo PP, Ruvolo VR, Jacamo R, Burks JK, Zeng Z, Duvvuri SR, Zhou L, Qiu Y, Coombes KR, Zhang N, Yoo SY, Pan R, Hail N, Konopleva M, Calin G, Kornblau SM, Andreeff M. The protein phosphatase 2A regulatory subunit B55α is a modulator of signaling and microRNA expression in acute myeloid leukemia cells. Biochim Biophys Acta 1843(9):1969-77, 2014. e-Pub 2014. PMID: 24858343.
Mak PY, Mak DH, Mu H, Shi Y, Ruvolo P, Ruvolo V, Jacamo R, Burks JK, Wei W, Huang X, Kornblau SM, Andreeff M, Carter BZ. Apoptosis Repressor with Caspase Recruitment Domain Is Regulated by MAPK/PI3K and Confers Drug Resistance and Survival Advantage to AML. Apoptosis 19(4):698-707, 2014. e-Pub 2014. PMID: 24337870.
Kojima K, Kornblau SM, Ruvolo V, Dilip A, Duvvuri S, Davis RE, Zhang M, Wang Z, Coombes KR, Zhang N, Qiu YH, Burks JK, Kantarjian H, Shacham S, Kauffman M, Andreeff M. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Blood 121(20):4166-74, 2013. e-Pub 2013. PMID: 23564911.
Shah N, Martin-Antonio B, Yang H, Ku S, Lee DA, Cooper LJ, Decker WK, Li S, Robinson SN, Sekine T, Parmar S, Gribben J, Wang M, Rezvani K, Yvon E, Najjar A, Burks JK, Kaur I, Champlin RE, Bollard CM, Shpall EJ. Antigen Presenting Cell-Mediated Expansion of Human Umbilical Cord Blood Yields Log-Scale Expansion of Natural Killer Cells with Anti-Myeloma Activity. PLoS One 8(10):1-9, 2013. e-Pub 2013. PMID: 24204673.
Mazurek N, Byrd JC, Sun Y, Hafley M, Ramirez K, Burks JK, Bresalier RS. Cell-surface galectin-3 confers resistance to TRAIL by impeding trafficking of death receptors in metastatic colon adenocarcinoma cells. Cell Death Differ 19(3):523-33, 2012. e-Pub 2012. PMID: 21941373.
Kidd S, Spaeth E, Watson K, Burks JK, Lu H, Klopp A, Andreeff M, Marini FC. Origins of the tumor microenvironment: quantitative assessment of adipose-derived and bone marrow-derived stroma. PLoS One 7(2):e30563, 2012. e-Pub 2012. PMID: 22363446.
Ruvolo PP, Zhou L, Watt JC, Ruvolo VR, Burks JK, Jiffar T, Kornblau S, Konopleva M, Andreeff M. Targeting PKC Mediated Signal Transduction Pathways Using Enzastaurin to Promote Apoptosis in Acute Myeloid Leukemia-derived Cell Lines and Blast Cells. J Cell Biochem 112(6):1696-707, 2011. e-Pub 2011. PMID: 21360576.
Kojima K, Burks JK, Arts J, Andreeff M. The novel tryptamine derivative JNJ-26854165 induces wild-type p53- and E2F1-mediated apoptosis in acute myeloid and lymphoid leukemias. Mol Cancer Ther 9(9):2545-57, 2010. e-Pub 2010. PMID: 20736344.
Xing D, Ramsay AG, Gribben JG, Decker WK, Burks JK, Munsell M, Li S, Robinson SN, Yang H, Steiner D, Shah N, McMannis JD, Champlin RE, Hosing C, Zweidler-McKay PA, Shpall EJ, Bollard CM. Cord blood natural killer cells exhibit impaired lytic immunological synapse formation that is reversed with IL-2 exvivo expansion. J Immunother 33(7):684-96, 2010. e-Pub 2010. PMID: 20664358.
Zhang W, Konopleva M, Burks JK, Dywer KC, Schober WD, Yang JY, McQueen TJ, Hung MC, Andreeff M. Blockade of mitogen-activated protein kinase/extracellular signal-regulated kinase kinase and murine double minute synergistically induces Apoptosis in acute myeloid leukemia via BH3-only proteins Puma and Bim. Cancer Res 70(6):2424-34, 2010. e-Pub 2010. PMID: 20215498.
Ling X, Marini F, Konopleva M, Schober W, Shi Y, Burks JK, Clise-Dwyer K, Wang RY, Zhang W, Yuan X, Lu H, Caldwell L, Andreeff M. Mesenchymal Stem Cells Overexpressing IFN-ß Inhibit Breast Cancer Growth and Metastases through Stat3 Signaling in a Syngeneic Tumor Model. Cancer Microenviron 3(1):83-95, 2010. e-Pub 2010. PMID: 21209776.
Serda RE, Gu J, Burks JK, Ferrari K, Ferrari C, Ferrari M. Quantitative mechanics of endothelial phagocytosis of silicon microparticles. Cytometry A 75(9):752-60, 2009. e-Pub 2009. PMID: 19610127.
Fiegl M, Samudio I, Clise-Dwyer K, Burks JK, Mnjoyan Z, Andreeff M. CXCR4 expression and biologic activity in acute myeloid leukemia are dependent on oxygen partial pressure. Blood 113(7):1504-12, 2009. e-Pub 2009. PMID: 18957686.
Zhang C, Zhang MX, Shen YH, Burks JK, Li XN, LeMaire SA, Yoshimura K, Aoki H, Matsuzaki M, An FS, Engler DA, Matsunami RK, Coselli JS, Zhang Y, Wang XL. Role of NonO-histone interaction in TNFalpha-suppressed prolyl-4-hydroxylase alpha1. Biochim Biophys Acta 1783(8):1517-28, 2008. e-Pub 2008. PMID: 18439917.
Zhang C, Zhang MX, Shen YH, Burks JK, Zhang Y, Wang J, LeMaire SA, Yoshimura K, Aoki H, Coselli JS, Wang XL. TNF-alpha suppresses prolyl-4-hydroxylase alpha1 expression via the ASK1-JNK-NonO pathway. Arterioscler Thromb Vasc Biol 27(8):1760-7, 2007. e-Pub 2007. PMID: 17478756.
Burks JK, Summers MD, Braunagel SC. BV/ODV-E26: a palmitoylated, multifunctional structural protein of Autographa californica nucleopolyhedrovirus. Virology 361(1):194-203, 2007. e-Pub 2007. PMID: 17169392.
Saksena S, Summers MD, Burks JK, Johnson AE, Braunagel SC. Importin-alpha-16 is a translocon-associated protein involved in sorting membrane proteins to the nuclear envelope. Nat Struct Mol Biol 13(6):500-8, 2006. e-Pub 2006. PMID: 16715095.
Braunagel SC, JK B, Rosas-Acosta G, Harrison RL, Ma H, Summers MD. Mutations within the Autographa californica nucleopolyhedrovirus FP25K gene decrease the accumulation of ODV-E66 and alter its intranuclear transport. J Virol 73(10):8559-70, 1999. e-Pub 1999. PMID: 10482609.
Pourebrahim R, Montoya RH, Alaniz Z, Ostermann L, Lin P, Liu B, Ayoub E, Burks JK, Andreeff M. Mdm2 is essential for the emergence, maintenance and hematopoietic support of the bone marrow mesenchymal stromal cells. Journal of Clinical Investigation.
al BE. Tumor resident microbes modulate the therapeutic immune response via mast cells recruitment. Nature.
Dondossola E, Maksimovic S, Boscolo NC, Posta LL, Barrios S, Moussa MJ, Pesquera P, Gentile E, Li W, Chen J, Gomez J, Basi A, JK B, Gao J, Alvarez-Breckenridge C, Campbell AM. Antiangiogenic tyrosine kinase inhibitors have differential efficacy in clear cell renal cell carcinoma with bone metastases. Cancer Research Communications.
et al AM. Degeneration of tumor associated nerves promotes resistance to anti-PD-1 therapy in head and neck cancer patients. Nature.
Maksimovic S, Boscolo N, Posta LL, Barrios S, Moussa MJ, Gentile E, Pesquera P, Li W, Chen J, Gomez J, Basi A, Burks J, Alvarez-Breckenridge C, Gao J, Campbell M, Dondossola AE. Antiangiogenic tyrosine kinase inhibitors have differential efficacy in clear cell renal cell carcinoma in bone. Cancer Research Communications.
al BE. Chromatin Introversion in Sickle Cell Disease Drives T cell Ferroptosis. Nature.
Hui Dai JZ, Huo L, Burks JK, McGrail D, Lin S. Suppression of cytosolic DNA degradation promotes breast cancer immunogenicity via a STING-independent pathway. Science Translational Medicine.
Carstens J, Krishnan S, Rao A, Ferri-Borgogno S, JK AB. Spatial Omics technologies and applications: the how of seeing the where of biological systems. Nature Reviews Molecular Cell Biology.
Liu Y, Han G, Zhang Y, Min J, Wang R, Pei G, Cho KS, Dai E, Chu Y, Jiang J, Zhang D, Yan X, Liu Y, Guerrero PA, Sinjab A, Serrano A, Li M, Futreal A, Ajani JA, Solis Soto LM, Kadara H, Jazaeri AA, Maitra A, Paradiso F, Basi A, Burks JK, Rajapakshe KI, Hwang TH. Conserved Spatial Subtypes and Cellular Neighborhoods of Cancer-Associated Fibroblasts Revealed by High-Plex Single-Cell Spatial Multi-Omics. Cancer Cell.
Hui Dai JZ, Huo L, Burks JK, McGrail D, Lin S. Suppression of cytosolic DNA degradation promotes breast cancer immunogenicity via a STING-independent pathway. Journal of Clinical Investigation.
Maksimovic S, Boscolo N, Posta LL, Barrios S, Moussa M, Gentile E, Pesquera P, Li W, Chen J, Gomez J, Basi A, Burks J, Alvarez-Breckenridge C, Gao J, Campbell M, Dondossola AE. Antiangiogenic tyrosine kinase inhibitors have differential efficacy in clear cell renal cell carcinoma with bone metastases. Clinical Cancer Research.
Dondossola E, Maksimovic S, Boscolo NC, Posta LL, Barrios S, Moussa MJ, Pesquera P, Gentile E, Li W, Chen J, Gomez J, Basi A, JK B, Gao J, Alvarez-Breckenridge C, Campbell AM. Antiangiogenic tyrosine kinase inhibitors have differential efficacy in clear cell renal cell carcinoma with bone metastases. Nature.
Zhao Z, Hu B, Deng Y, Soeung M, Yao J, Zhang Y, Gong P, Huang LA, Jiang Z, Gao J, Peng S, Nguyen TK, Karki M, Lim B, Yee C, Burks JK, Zhang Q, Ma L, Gao J, Tannir NM, Han L, Yu D, Wang L, Curran MA, Genovese G, Gan B, Li W, Msaouel P, Yang L, Lin C. T cell ferroptosis associated with chromatin introversion impairs anti-tumor immunity in sickle cell disease. Cell.
et al ED. Antiangiogenic tyrosine kinase inhibitors have differential efficacy in clear cell renal cell carcinoma with bone metastases. Science Advances.
et al JC. Spatial Multiplexing and Omics: a primer on the current state-of-the art technologies and applications. Nature Reviews Methods Primers.
Ogata D, Creasy CA, Roszik J, Kim S, Fukuda Y, Cho SN, Torres-Cabala CA, Burks J, B Hoon DS, Grimm E, Bernatchez C, Ekmekcioglu S. Nitric Oxide regulated inflammatory microenvironment defines the treatment outcome of adoptive transfer of tumor-infiltrating lymphocytes in melanoma. Frontiers in Immunology, section Cancer Immunity and Immunotherapy.
al BE. Neural Landscape Drives Functional Outcomes of Patients with Oropharyngeal Squamous Cell Carcinoma. Science Translational Medicine.
Hui Dai JZ, Huo L, Burks JK, McGrail D, Lin S. Suppression of cytosolic DNA degradation promotes breast cancer immunogenicity via a STING-independent pathway. Science Advances.
al BE. Multimodal Spatial Proteomic Profiling in Acute Myeloid Leukemia. npj Precision Oncology.
al K. CD70 Expression in Treatment Naïve and Relapsed Acute Myeloid Leukemia Patients. Haematologica.
Sainz TP, Sahu V, Gomez JA, Dcunha NJ, Basi AV, Kettlun C, Sarami I, Burks JK, Sampath D. Role of the crosstalk B:neoplastic T follicular helper (TFH) cells in the pathobiology of nodal TFH cell lymphomas  . Laboratory Investigation.
Maksimovic S, Boscolo N, Posta LL, Barrios S, Moussa M, Gentile E, Pesquera P, Li W, Chen J, Gomez J, Basi A, Burks J, Alvarez-Breckenridge C, Gao J, Campbell M, Dondossola AE. Antiangiogenic tyrosine kinase inhibitors have differential efficacy in clear cell renal cell carcinoma with bone metastases. Journal of Experimental Medicine.
Dondossola E, Maksimovic S, Boscolo NC, Posta LL, Barrios S, Moussa MJ, Pesquera P, Gentile E, Li W, Chen J, Gomez J, Basi A, JK B, Gao J, Alvarez-Breckenridge C, Campbell AM. Antiangiogenic tyrosine kinase inhibitors have differential efficacy in clear cell renal cell carcinoma with bone metastases. Science Translational Medicine.

Invited Articles

Gabrusiewicz K, Li X, Wei J, Hashimoto Y, Marisetty AL, Ott M, Wang F, Hawke D, Yu J, Healy LM, Hossain A, Akers JC, Maiti SN, Yamashita S, Shimizu Y, Dunner K, Zal MA, Burks JK, Gumin J, Nwajei F, Rezavanian A, Zhou S, Rao G, Sawaya R, Fuller GN, Huse JT, Antel JP, Li S, Cooper L, Sulman EP, Chen C, Geula C, Kalluri R, Zal T, Heimberger AB. Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes. Oncoimmunology 7(4):e1412909, 2018. e-Pub 2018. PMID: 29632728.

Editorials

Burks JK. A model for where we live. Cell & Gene Therapy Insights 7(10):1513-1519, 2021.

Abstracts

et al LGDS. The immunological milieu of oropharyngeal squamous cell Carcinoma (OPC) according to HPV and smoking status and its influence on prognosis. 2024 ASCO Annual Meeting, 2024. e-Pub 2024.
Takahashi Y, Gomez J, Burks JK, Amit M, Bell D, Xie T, Hoke A, London N, Hanna EY. Evaluation of the Immune Microenvironment with Tumor Recurrence in Sinonasal Undifferentiated Carcinoma. J Neurol Surg B Skull Base, 2024. e-Pub 2024.
et al ES. Spatial multi-omics investigation of high-grade serous ovarian cancer tumor microenvironment provides insight into minimal residual disease and intrinsic chemoresistance. ASMS Conference on Mass Spectometry and Allied Topics, 2024. e-Pub 2024.
et al SE. Mass Spectrometry Imaging Reveals Molecular Changes Associated with Aging in Pancreatic Cancer. International Mass Spectrometry Imaging Society ~ 1st Annual Conference on Mass Spectrometry Imaging and Integrated Topics, 2023. e-Pub 2023.
et al SE. Mass Spectrometry Imaging Reveals Molecular Changes Associated with Aging in Pancreatic Cancer. Innovations In Cancer Prevention and Research Conference VI, 2023. e-Pub 2023.
et al KL. The Effects of a Glutamine-Free Diet on Tumor Progression and the Immune Landscape of the Ovarian Tumor Microenvironment. 2023 Summer Experience, 2023. e-Pub 2023.
Imanishi M, Cheng H, Kotla S, Lin S, Deswal A, Ko K, Samanthapudi V, Le N, Fujiwara K, Liao Z, Palaskas NL, Yusuf SW, Nurieva RI, Reyes-Gibby C, Yeung S, Amir ED, Burks JK, Kobayashi M, Yoshimoto M, Abe J. Multiparameter Mass Cytometry Reveals The Unique Response Of NaïVe B Cell Cd27- Subset With The Increase Of T-bet And Cd38 Expression After Radiation Therapy In Thoracic Cancer Patients. AHA, 2022. e-Pub 2022.
Kotla S, Imanishi M, Li S, Zhang A, Ko KA, K Samanthapudi VS, Lee L, Herrmann J, Lin S, Shoykhet MN, Shen YH, Schadler K, Nguyen MT, Gupte AA, Reyes-Gibby C, Yeung S, Palaskas NL, Cooke JP, Pownall HJ, Yoshimoto M, Fujiwra K, Hamilton D, Burks JK, Wang G, T Le NT, Abe J. Erk5 S496 Phosphorylation, but Not Erk5 Kinase Activation, Promotes Senescence-Associated Cell Growth (sacg) and Inflammation of Myeloid Cells and Atherosclerosis via Upregulating Sumoylation at a Novel Site (k518) on Nrf2 and Aryl Hydrocarbon Receptor. AHA, 2022. e-Pub 2022.
Burks JK. Cellular Cartography by Mass Cytometry. 2nd Future of Immunology Symposium, 2022. e-Pub 2022.
Reuben JM, Wang X, ManyamGC, Wang J, Shao SH, Bertucci, Finetti P, Krishnamurthy S, Phi T, Hanh L, Pearson T, Burks JK, Cohen, EN, Hu M, Navin N, Shen Y, Zhang X, Tripathy D, Ueno NT. Remodeling the inflammatory breast cancer tumor microenvironment to enhance immunotherapy: Novel therapeutic development. AACR 2021, 2022. e-Pub 2022.
et al HN. The central nervous system immune cell interactome is a function of cancer lineage, tumor microenvironment and STAT3 expression. AACR Annual Meeting 2022, 2022. e-Pub 2022.
Ferri-Borgogno S, Zhu Y, Sheng J, Burks JK, Gomez J, Wong KK, Wong ST, Mok SC. Long-term ovarian cancer survivors: spatial transcriptomics depict ligand-receptor crosstalk heterogeneity at the tumor-stroma interface. Cancer Research, 2022. e-Pub 2022.
de Sousa LG, McGrail DJ, Li K, Marques-Piubelli ML, Gonzalez C, Dai H, Ferri-Borgogno S, Godoy M, Burks JK, Lin S, Bell D, Ferrarotto R. Spontaneous tumor regression following COVID-19 vaccination. J Immunother Cancer 10(3), 2022. e-Pub 2022.
al HE. T-cell interactions vary between tumor microenvironments. Northwestern University ~ Feinberg School of Medicine, 2022. e-Pub 2022.
et al LGDS. Single-Cell Immune Mapping of Adenoid Cystic Carcinoma (ACC) Reveals Potential Therapeutic Targets for the aggressive Solid subtype. 2022 ASCO Annual Meeting, 2022. e-Pub 2022.
et al SE. Immune Related Oxidative Stress Biomarkers in Tumor Immune Microenvironment Provide Predictive Information in Immunotherapy Response. SITC 37th Annual Meeting & Pre-Conference Programs, 2022. e-Pub 2022.
Li H, Wang Y, Lin K, Venkadakrishnan VB, Bakht M, Shi W, Meng C, Zhang J, Tremble K, Liang X, Song JH, Feng X, Van V, Deng P, Burks JK, Aparicio A, Keyomarsi K, Chen J, Lu Y, Beltran H, Zhao D. CHD1 Promotes SensitivityCHD1 promotes sensitivity to Aurora kinase inhibitors by suppressing interaction of AURKA with its coactivator TPX2. Cancer Research 82(17), 2022. e-Pub 2022.
Bentebibel S, Johnson D, Amariae R, McGrail D, Lecagoonporn S, Haymaker C, Duose D, Wani K, Safa H, Glitza IC, Patel SP, Wong MK, Tawbi H, Burks JK, Yang X, Hwu P, Yee C, Davies MA, Murthy R, Suhendan Ekmekcioglu CB, Diab A, Lizée G. CT039 - Intratumoral CD40 agonist sotigalimab with pembrolizumab induces broad innate and adaptive immune activation in local and distant tumors in metastatic melanoma. Cancer Research, 2022. e-Pub 2022.
et al SK. An ERK5-NRF2 axis mediates senescence-associated stemness and atherosclerosis. 29th Annual Conference of the Society for Redox Biology and Medicine, 2022. e-Pub 2022.
Arrieta V, Chen AX, Kane J, Kang SJ, Kassab C, Dmello C, Zhao J, Burdett K, Upadhyayula P, Chang C, Shilati J, Jaishankar D, Chen L, Gould A, Zhang D, Yuan J, Zhao W, Ling X, Burks JK, Laffleur B, Amidei C, Bruce JN, Lukas RV, Yamaguchi JT, Cieremans D, Rothschild G, Basu U, McCord M, Brat D, Zhang H, Cooper LA, Zhang B, Sims P, Cloughesy T, Prins R, Canoll P, Stupp R, Heimberger AB, Horbinski C, Iwamoto F, Rabadan R, Sonabend AM. BIOM-31. ERK1/2 PHOSPHORYLATION PREDICTS SURVIVAL FOLLOWING ANTI-PD-1 IMMUNOTHERAPY IN RECURRENT GLIOBLASTOMA. Neuro-Oncology 23(Supplement_6):vi17-vi17, 2021. e-Pub 2021.
Carstens JL, Yang S, de Sampaio PC, Zheng X, Barua S, McAndrews KM, Rao A, Burks JK, Rhim AD, Kalluri R. Abstract PO-059: Epithelial/mesenchymal identity dictates pancreatic cancer cell metastasis. Cancer Research 81(22_Supplement):PO-059-PO-059, 2021. e-Pub 2021.
Najem H, Marisetty A, Horbinski C, Burks JK, Heimberger AB. LMD-20. Immune Suppressive Macrophages and Signal Transducer and Activator of Transcription 3 (STAT3) Expression are common in Melanoma Leptomeningeal Disease. Neuro-Oncology Advances 3, 2021. e-Pub 2021.
Cun HT, Ferri-Borgogno S, Cheng R, Kim J, Han GH, Burks JK, Lu KH, Mok SC. The immune landscape of recurrent ovarian carcinoma. Cancer Research 81(13_Supplement):2744-2744, 2021. e-Pub 2021.
Montoya RH, Pourebrahim R, Alaniz Z, Ostermann L, Burks JK, Andreeff M. Osterix Marks a Distinct Population of Circulatory Bone Marrow Mesenchymal Stem Cells That Is Increased upon Oncogenic Stress. Blood 136, 2020. e-Pub 2020.
Pourebrahim R, Montoya RH, Alaniz Z, Ostermann L, Ayoub E, Lin PP, Burks JK, Andreeff M. Mdm2 Haplo-insufficiency in Hematopoietic and Mesenchymal Progenitor Cells Results in Cell Death. Blood 136:10, 2020. e-Pub 2020.
Chandra V, Zhang Y, Riquelme E, Dutta P, Quesada PR, Rakoski A, Zoltan M, Arora N, Baydogan S, Horne W, Burks JK, Xu H, Hussain P, Wang H, Gupta S, Maitra A, Bailey JM, Moghaddam SJ, Banerjee S, Sahin I, Bhattacharya P, McAllister F. Abstract PO-014: Interleukin 17 induced-neutrophil extracellular traps (NETs) mediate resistance to checkpoint blockade in pancreatic cancer. Cancer Research 80(22_Supplement):PO-014-PO-014, 2020. e-Pub 2020.
Cun H, Hinchcliff EM, Zhu Y, Ferri-Borgogno S, Cheng R, Burks JK, Wong STC, Jazaeri AA, Mok SC. Identification of a novel biomarker response in a prospective clinical trial of immune checkpoint blockade in high grade ovarian carcinoma. Gynecologic Oncology 159:143, 2020. e-Pub 2020.
Lee S, Zhao L, Rojas C, Bateman NW, Yao H, Lara OD, Jazaeri AA, Liu J, Burks JK, Fleming ND, Lu KH, Westin SN, Coleman RL, Mills GB, Zhang J, Conrads TP, Maxwell GL, Futreal PA, Sood AK. A high-depth multi-omics analysis of clinically defined subsets of high-grade serous ovarian cancer. Gynecologic Oncology 159:77, 2020. e-Pub 2020.
Zhu Y, Ferri-Borgogno S, Sheng J, Yeung T, Burks JK, Cappello P, Jazaeri AA, Kim J, Han GH, Birrer MJ, Mok SC, Wong ST. Deep learning on image-omics data in identifying prognostic immune biomarkers for ovarian cancer, 2020. e-Pub 2020.
Montoya RH, Pourebrahim R, Alaniz Z, Ostermann LB, JK B, Andreeff M. High-Dimensional Single-Cell Proteomic Analysis Reveals Therapeutic Vulnerabilities in Relapsed/Refractory AML By Concomitant Analysis of Cell Surface Antigens, Signaling Pathways and Anti-Apoptotic Proteins. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA 20:S206-S207, 2020. e-Pub 2020.
Cun H, Hinchcliff EM, Zhu Y, Ferri-Borgogno S, Cheng R, Burks JK, Wong STC, Jazaeri AA, Mok SC. Identification of a novel biomarker response in a prospective clinical trial of immune checkpoint blockade in recurrent ovarian carcinoma. Cancer Research, 2020. e-Pub 2020.
Rocha P, Solis L, Parra E, Shi O, Mino B, Sinha VC, Rinkenbaugh A, Tamegnon A, Duncan M, Lu W, Jiang M, Kakarala L, Burks JK, Piwnica-Worms H, Haymacker C, Teztlaff M, Wistuba I, Francisco-Cruz AA. Immuno-oncology panel optimization for Imaging Mass Cytometry and digital image analysis of tumor tissues. AACR Annual Meeting 2020; April 27-28, 2020 and June 22-24, 2020; Philadelphia, PA 80(16), 2020. e-Pub 2020.
Kotla S, Zhang A, Imanishi M, Ko KA, Lin SH, Gi YJ, Fujiwara K, Burks JK, Le N, Hamilton DJ, Abe AJ. Stress-induced premature aging mediated by mitochoindrial hibernation promotes atherosclerosis. IVBM 2020, 2020. e-Pub 2020.
Zhu Y, Sheng J, Ferri-Borgogno S, Yeung T, Burks JK, Mok SC, Wong ST. An artificial intelligence pipeline for imaging mass cytometry data analysis and it application in ovarian cancer prognostic biomarker discovery. Cancer Research 80(16_Supplement):854-854, 2020. e-Pub 2020.
Rocha P, Solis L, Parra E, Shi O, Mino B, Sinha V, Rinkenbaugh AL, Tamegnon A, Duncan M, Lu W, Jiang M, Kakarala L, Burks JK, Piwnica-Worms H, Teztlaff M, Wistuba I, Francisco-Cruz A. Immuno-oncology panel optimization for Imaging Mass Cytometry and digital image analysis of tumor tissues. Cancer Research(16_Supplement):2679-2679, 2020. e-Pub 2020.
Burks JK, Chanthaphavong S, Hollman T, Loomis C, Mezzano V. Beyond Spatial Transcriptomics: Tissue Systems Biology. Journal of biomolecular techniques: JBT 31(Suppl):S33, 2020. e-Pub 2020.
Imanishi M, Ko KA, Kotla S, Thomas TN, Gi YJ, Wang Y, Fujiwara K, Savage H, Velatooru LR, Schadler K, Shen YH, Le NT, Burks JK, Abe J. Abstract 320: Novel Simultaneous Multiplexed Imaging With Subcellular Resolution in Atherosclerosis Plaque by Mass Cytometry (Imaging Mass Cytometry). Arteriosclerosis, Thrombosis, and Vascular Biology 40(Suppl_1):A320-A320, 2020. e-Pub 2020.
Ott M, Kassab C, Marisetty A, Hashimoto Y, Wei J, Zamler D, Leu J, Tomaszowski K, Sabbagh A, Fang D, Gupta P, Priebe W, Zielinski RJ, Burks JK, Long JP, Kong L, Fuller GN, DeGroot J, Sulman EP, Heimberger AB. Radiation with STAT3 Blockade Triggers Dendritic Cell–T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy. Clinical Cancer Research, 2020. e-Pub 2020.
Carstens JL, de Sampaio PC, Barua S, Wang H, Burks JK, Rao A, LeBleu VS, Kalluri AR. Abstract PR08: Intratumoral T-cell distribution in murine and patient pancreatic cancer correlates with tissue heterogeneity and survival. CANCER RESEARCH 79(24), 2019. e-Pub 2019.
Burks JK. Mass Cytometry Why Multiplex. Journal of Biomolecular Techniques: JBT 30(Suppl):S54, 2019. e-Pub 2019.
Swaminathan M, Morita K, Yuanqing Y, Wang F, Burks JK, Gumbs C, Little L, Tippen S, Thornton R, Coyle M, Zhang J, Song X, DiNardo CD, Jabbour EJ, Kadia TM, Cortes JE, Daver NG, Pemmaraju N, Patel K, Garcia-Manero G, Kantarjian HM, Bueso-Ramos CE, Futreal A, Takahashi K. Clinical heterogeneity of AML is associated with mutational heterogeneity. Blood 132:5240, 2019. e-Pub 2019.
Andreeff M, Zeng J, Soragni A, Ruvolo V, Carter BZ, Ishizawa J, Burks JK, Eisenberg D. Targeting Misfolded p53 and p53 Aggregation to Overcome Resistance to Apoptosis in Acute Myeloid Leukemia. Blood 134:3786, 2019. e-Pub 2019.
Zhu Y, Yeung, Tsz-Lun, Sheng J, Hinchcliff, Moss E, Burks JK, Jazaeri, Amir A, Mok, Samuel, Wong S. An image informatics pipeline for imaging mass cytometry to characterize the immune landscape in pre- and on-treatment immune therapy and its application in recurrent platinium-resistant epithelial ovarian cancer. 2019 IEEE EMBS International Conference on Biomedical & Health Informatics (BHI):1-4, 2019. e-Pub 2019.
Rizvi Y, Burks JK, Mak D, Meric-Bernstam F, Tapia C. Image Mass Cytometry to Detect Immune Cells and Predictive Biomarkers in Formalin-Fixed and Paraffin-Embedded Tissue. Laboratory Investigation 99. e-Pub 2019.
et al CT. Image Mass Cytometry to Detect Immune Cells and Predictive Biomarkers in Formalin-Fixed and Paraffin-Embedded Tissue. USCAP 2019 Annual Meeting, 2019. e-Pub 2019.
et al CK. Comprehensive Spatial Characterization of Immune Cells in the Brain Tumor Microenvironment. Society of Neuro Oncology, 2019. e-Pub 2019.
Yuan B, Ly S, Nguyen K, Tran V, Maldonado K, Kinglsey C, Burks JK, Zhou X, deCrombrugghe B, Andreeff M, Battula VL. Acute myeloid leukemia expands osteoprogenitor rich niche in the bone marrow but resorbs mature bone causing osteopenia/osteoporosis in animal models. Blood 132:86, 2018. e-Pub 2018.
Han L, Qiu P, Jorgensen JL, Mak D, Burks JK, McQueen T, Zeng Z, Ravandi F, Roboz GJ, Kantarjian HM, Kornblau SM, Andreeff M, Guzman ML, Konopleva MY. Single-cell mass cytometry characterizes phenotypic and functional heterogeneity in acute myeloid leukemia at diagnosis, in remission and relapse. Blood 132:912, 2018. e-Pub 2018.
Saldarriaga O, Booth A, Burks JK, Utay NS, Ferguson M, Beretta L, Stevenson-Lerner HL. Multispectral Imaging Reveals Unique Macrophage Profiles Associated with Type of Liver Disease and Fibrosis Stage. HEPATOLOGY 68, 2018. e-Pub 2018.
Morita K, Wang F, Yan Y, Burks JK, Gumbs C, Latasha L, Tippen S, Thornton R, Coyle M, Zhang J, Xingzhi S, DiNardo C, Jabbour E, Andreeff M, Cortes J, Konopleva M, Patel K, Garcia-Manero G, Kantarjian H, Bueso-Ramos C, Futreal P, Takahashi K. The Landscape of Genotype-Phenotype Correlation in AML. Clinical Lymphoma, Myeloma and Leukemia 18:S209-S210, 2018. e-Pub 2018.
Dottino JA, Jiang Y, Shah S, Celestino J, Watson E, Zhang Q, Chisholm G, Burks JK, Mikos A, Lu KH, Yates MS. Novel intrauterine polymer system delivers everolimus at biologically active levels in rats. SGO 49th Annual Meeting on Women's Cancer, 2018. e-Pub 2018.
Hokanson J, McCarthy RL, Benton C, AlRawi A, Sun J, Mak DH, Burks JK, Andreeff M. CLEAN Corrects Variations in CyTOF Sample Preparation. CYTO 2016, 2016. e-Pub 2016.
Hokanson J, Wakefield C, Weinstein J, Andreeff M, Burks JK. High Dimensional Cytometry Data Visualization Using Parallel Coordinates. CYTO 2016, 2016. e-Pub 2016.
Ramsay AG, D-X X, Decker WK, Burks JK, Wierda WG, Gribben JG, Shpall EJ. Compared to Adult Peripheral Blood T Cells, Cord Blood T Cells Show Enhanced Immunological Recognition of Chronic Lymphocytic Leukemia Tumor Cells 112(2333), 2008. e-Pub 2008.
Fiegl M, Samudio IJ, Dwyer KC, Burks JK, Fritsche H, Mnjoyan ZH, Andreeff M. CXCR4 Expression and Biological Activity Is Dependent on Oxygen Partial Pressure in Acute Myeloid Leukemia. Blood 112(11), 2008. e-Pub 2008.
Zhang W, Konopleva M, Burks JK, Dywer K, Schober W, Yang JY, McQueen T, Hung MC, Andreeff M. Apoptosis induction in acute myeloid leukemia by inhibition of MEK and MDM2 is strongly associated with the BH3-only proteins Puma and Bim, 2008. e-Pub 2008.
M-X Z, Zhang C, Shen YH, Zhang L, Burks JK, Wang J, Coselli JS, Wang XL. Endogenous 27nt microRNA inhibits eNOS Expression through DNA Methylation, 2006. e-Pub 2006.
M-X Z, Shen YH, Zhang C, Burks JK, LeMaire SA, Wang J, Coselli JS, Wang XL. Endogenous eNOS-Specific 27nt MicroRNA is derived through Pre-mRNA Splicing, 2006. e-Pub 2006.
Braunagel SC, Saksena S, Burks JK, Johnson AE, Summers MD. Importin alpha-16: a translocon-associated protein potentially involved in sorting integral membrane proteins to the nuclear envelope, 2006. e-Pub 2006.
Zhang C, M-X Z, Shen YH, Burks JK, Zhang Y, LeMaire SA, Coselli JS, Wang XL. TNF{alpha} Suppresses Prolyl-4-Hydroxylase a (I) (P4Ha(I)) Expression and Collagen Processing in Aortic SMCs via JNK Pathway, 2006. e-Pub 2006.
Andreef M, Chang K, Ji Y, Muftuoglu M, Mak PY, Basyal M, Ostermann L, Burks JK, Ly C, Mu H, Fogler WE, Magnani JL, Lesegretain A, Zal M, Zal T, Carter BZ, Zhang W. Combinatorial CXCR4/E-Selectin Inhibition is Required to Overcome Microenvironment-Mediated Resistance to BCL-2 and FLT3-targeted Therapies in Acute Myeloid Leukemias. ESH Microenvironment Conference.
et al BJ. CD38 Activation by Disturbed Flow (d-flow) Promotes Endothelial Cell (EC) Senescence-Associated Stemness (SAS) through Glutaminolysis Enhanced by Pyruvate Dehydrogenase (PDH) Inhibition, Leading to Atherothrombosis. American Heart Association Scientific Sessions 2024.
Wang B, Reville PK, Jelloul FZ, Desai PN, Borges P, Ly C, Veletic I, Dasdemir E, JK B, Tang G, Guo S, Vaugh NR, Baran N, Deng Q, Matthews J, Gunaratne PH, Antunes DA, Ekmekcioglu S, Sasaki K, Garcia M, Cuglievan B, Hao D, Daver N, Green MR, Konopleva M, Futreal A, Post SM, Abbas HA. IFNγ Signaling in Acute Myeloid Leukemia Mediates Immunomodulation and Reveals Therapeutic Strategies. ASH 2023.
Najem H, McCortney K, Steffens A, Tripathi S, Walshon J, DeCuypere MG, Brandenburg R, Hoerich D, James CD, Lesniak MS, Sonabend AM, Chandler JP, Tate M, Burks JK, Horbinski C, Heimberger AB. Immune Spatial Differences Between Short and Long-term Surviving Glioblastoma Patients. AAI Meeting 2023.
Hui Dai JZ, Huo L, Burks JK, McGrail D, Lin S. Suppression of cytosolic DNA degradation promotes breast cancer immunogenicity via a STING-independent pathway. Cancer Research.
Najem H, Tripathi S, McCortney K, Horak VJ, Leonard K, Steffens A, Walshon J, Horbinski CM, Wadhwani NR, James DC, Lam S, Lesniak MS, Burks JK, Heimberger AB, DeCuypere MG. Pilocytic astrocytomas show evidence of intrinsic immune surveillance and activation within the tumor microenvironment. SNO.
Seeley, Erin, Gamal, Basant, Basi, Akshay, Patterson, Heath N, Zhang, Wanqiu, Mantas, Maria Jose Q, Ly, Alice, Verbeeck, Nico, Claesen, Marc, Jazaeri, Amir, Burks, Jared, Mok, Samuel, Ferri-Borgogno, Sammy. Using spatial multi-omics to investigate the contribution of tumor microenvironment to minimal residual disease and intrinsic chemoresistance of high-grade serous ovarian cancer. IMSIS Conference 2024.
et al BJ. Disturbed Flow (d-flow)-induced Endothelial Senescence-Associated Stemness (SAS): Unveiling the Impact of CD38 and LATS1/2 Depletion on Atherothrombosis Development. American Heart Association Scientific Sessions 2024.
Desai, al P. Paired Single Cell Transcriptomic and Repertoire Profiling of CD8 Cells in Acute Myeloid Leukemia Reveals Distinct Functional States at Time of Diagnosis and Therapy Resistance That Informs Patient Outcomes. AACR Annual Meeting 2022.
al AE. Immunosenescence in cardio-oncology. APS Cardio-Oncology Session.
et al ZR. Multimodal spatial transcriptomics and proteomics analysis of the resectable NSCLC ecosystem following neoadjuvant chemoimmunotherapy. SITC 39th Annual Meeting & Pre-Conference Programs.
et al SE. Quantitative and spatial characteristics of TIL in inflammatory neighborhoods of advanced melanoma tumors. SITC 38th Annual Meeting & Pre-Conference Programs.
et al ZR. Multimodal spatial transcriptomics and proteomics analysis of the resectable NSCLC ecosystem following neoadjuvant chemoimmunotherapy. AACR 2024.
Truong DD, Arslan E, Krishnan S, Agyemang C, Kochat V, Divenko M, Ingram D, Segura RL, Basi A, Gomez J, Beird HC, Wu C, Burks JK, Futreal P, Lazar A, Rai K, Ratan R, Daw NC, Hayes-Dixon A, Ludwig AJ. Multi-Omic Analysis of Desmoplastic Small Round Cell Tumors Reveal Distinct Lineages. CTOS 2023.
Burks JK, Seeley E, Ferri-Borgogno S, Gamal B, Basi A, Patterson H, Zhang W, Mantas M, Ly A, Verbeeck N, Claesen M, Jazaeri A, Mok S. Using spatial multi-omics to investigate the contribution of tumor microenvironment to minimal residual disease and intrinsic chemoresistance of high-grade serous ovarian cancer. SITC 2024.

Book Chapters

Quesada, PR, Riquelme Sanchez, EM, Burks, JK, Rakoski, A, Sahin, I, McAllister, F. Assessment of the Murine Tumor Microenvironment by Multiplex Immunofluorescence, 107-127, 2022.
Chandra V, McAllister F, JK Burks. Cytometry of Mass for Murine Immunoprofiling. In: Methods Mol Biol, 129-137, 2022.
Burks JK. Imaging tools for cellular uptake and intracellular trafficking. In: Mass transport of Nanocarriers. Pan Stanford Publishing Pte. Ltd, 221-240, 2012.

Less

Selected Presentations & Talks

Local Presentations

2025. Charting New Territories: Innovations in Spatial Biology and Translational Research. Invited. ISBI 2025 International Symposium on Biomedical Imaging. Houston, Texas, US.
2024. Institutional Research Resources. Invited. Research Grand Rounds. Houston, Texas, US.
2024. Cellular Cartographers: Charting the Unseen with Advanced Multi-Omics. Invited. Research Grand Rounds. Houston, Texas, US.
2024. Multi-plex Multi-Omics: the Future of Spatial Biology. Invited. The Data Science Forum. Houston, Texas, US.
2024. Spatial Proteomics. Invited. XIII Proteomics Workshop, BR.
2024. Institutional Resources. Invited. Next Gen Colloquium. Houston, Texas, US.
2024. Spatial Biology: Technological Networks. Invited. Understanding our Technologies. Houston, Texas, US.
2024. Multiple Multi-Omics. Invited. Metabolism in Cancer Symposium. Houston, Texas, US.
2024. Future of Spatial Biology, integration of multiplex multi-omics. Invited. Metabolism in Cancer Symposium. Houston, Texas, US.
2024. Multiplex Multi-Omics: The Future of Spatial Biology. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2024. Multiplex Multi-Omics: the future of spatial biology. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2023. Dissecting tissue and diseases: multimodal approaches for spatial analysis. Conference. Lunaphore. Houston, TX, US.
2023. Flow Cytometry & Cellular Imaging Core Facilities Updates. Conference. Bio-Techne. Houston, TX, US.
2023. Innovative Technology. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2023. Full Circle. Conference. Akoya User Group Meeting. Houston, TX, US.
2023. Technological Networks Reveal Cellular Networks. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2021. Emerging Technologies in the Flow Cytometry & Cell SIgnaling Core Facility at North Campus. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2020. Q & A. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2020. Creative Problem Solving. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2019. Multiplex Imaging. Conference. Texas Histo Regional Meeting. Houston, TX, US.
2019. 1st Annual GCC Translational Imaging Symposium. Conference. Gulf Coast Consortia for Quantitative Biomedical Science. Houston, TX, US.
2019. Composition versus Construction. Conference. FLOWTEX 2019. Houston, TX, US.
2018. Why Multiplex?. Conference. University of Texas MD Anderson Cancer Center. Houston, TX, US.
2018. Put your career in gear. Conference. Baylor College of Medicine, Houston Methodist Research Institute, MD Anderson Cancer Center, Rice University, Texas A&M, Health Science Center, Texas Childrens Hospital, University of Houston and The University of Texas Health Science Center at Houston. Houston, TX, US.
2016. Bitplane Imaris User Group Meeting. Conference. Baylor College of Medicine. Houston, TX, US.
2016. Mass Cytometry Basics. Conference. The University of Texas MD Anderson Cancer Center. Houston, TX, US.
2014. Image Analysis Tools and the Opal Imaging Technology. Conference. MD Anderson Cancer Center Flow Cytometry & Cell Signaling Core Facility. Houston, TX, US.
2014. 10 Color Labeling. Conference. MD Anderson Cancer Center Flow Cytometry & Cell Signaling Core Facility. Houston, TX, US.

Regional Presentations

2025. Cellular Cartographers: Charting the Unseen with Advanced Multi-Omics. Invited. Cancer Center Seminar. Charlottesville, VA, US.
2025. Cellular Cartographers: Charting the Unseen with Advanced Multi-Omics. Invited. Core Knowledge Series. Cold Spring Harbor, NY, US.
2025. Cellular Cartographers: Charting the Unseen with Advanced Multi-Omics. Invited. Veterinary Pathobiology Seminar Series. College Station, Texas, US.
2024. Masterclass Series - Multiplex Multi-Omics - The Future of Spatial Biology. Conference. Visiopharm. (Virtual), US.
2024. Research records: The what and the how. Conference. The University of Texas MD Anderson Cancer Center, US.
2024. LEADing Teams Core Cohort 6: High Reliability Organization Deep Dive. Conference. The University of Texas MD Anderson Cancer Center. Houston, US.
2024. Spatial Biology ~ Technology Pathways. Conference. Fortis Life. (Virtual), US.
2023. Engaging Technological Networks to Solve Cellular Networks: Moving Beyond Spatial Phenotyping to Function. Conference. Frontline Genomics. (Virtual), US.
2023. Facility & Technology Update. Conference. The University of Texas MD Anderson Cancer Center. (Virtual), US.
2023. Spatial Biology Roundtable. Conference. Cell Signal. Raleigh, NC, US.
2022. Advancing discovery and translational research with innovations in spatial biology. Conference. Lunaphore. (Virtual), TX, US.
2022. Facilitating Discoveries by the Flow Cytometry and Cellular Imaging Core. Conference. The University of Texas MD Anderson Cancer Center. (Virtual), TX, US.
2021. High-plexed Cellular Cartography. Conference. The University of Texas at Austin. (Virtual), TX, US.
2021. Single Cell Technologies. Conference. The Neuro Degenerative Consortium. (Virtual), TX, US.
2019. Composition to Construction. Conference. Fluidigm. Dallas, TX, US.
2019. Composition versus Construction. Conference. Genentech. San Fransisco, CA, US.
2019. Immuno Club CyTOF Workshop. Conference. Immuno Club at MD Anderson Cancer Center, US.
2019. Mass Cytometry Why Multiplex. Conference. ABRF 2019. San Antonio, TX, US.
2017. Identifying the correct yellow brick road: The Direction of Multiplexed Imaging. Conference. Bethyl Labs, TX, US.
2014. Cancer Immunology Research Strategies for Multiplexed Biomarker Discovery ~ Translational studies in Quantitative Digital Pathology utilizing novel staining and imaging techniques. Conference. MD Anderson Cancer Center Flow Cytometry & Cell Signaling Core Facility. Houston, US.
2003. BV/ODV E26 localization in Spodoptera frugiperda cells suggests two models for protein trafficking. Conference. Texas A&M University. College Station, TX, US.

National Presentations

2025. Sound Explodes: Quiet Layers Ascend. Invited. AACR Lunaphore Dinner Symposium. Chicago, IL, US.
2024. Using spatial multi-omics to investigate the contribution of tumor microenvironment to minimal residual disease and intrinsic chemoresistance of high-grade serous ovarian cancer. Poster. Society for Immunotherapy of Cancer (SITC). Houston, TX, US.
2024. EACR Roundtable: Pioneering in the unknown: how to navigate through the spatial biology. Invited. The Spatial Biology Week 2024. (Virtual), US.
2024. Multiplex Multi-Omics, The Future of Spatial Biology. Invited. BioTrac Spatial Biology meeting. Germantown, MD, US.
2024. Novel Analysis Methods. Invited. 5th Annual AstraZeneca / Bio-Trac Spatial Biology Symposium. Gaithersburg, MD, US.
2024. Two Roads Diverged in Wood. Invited. Inflammatory Microenvironment and Tumor Cross Talk Working Group. (Virtual), US.
2024. Flow into the Future: Cytometry and Spatial Biology Explored. Invited. Standard Biotools. Edinburgh.
2024. Paving new roads in mass cytometry: Harmonizing multiplex modalities together and introducing a rapid, high throughput whole slide imaging to workflow. Invited. Standard Biotools. Edinburgh.
2024. Spatial Biology: pushing the boundaries of cancer research. Invited. San Diego, CA, US.
2024. Comet +: Two roads diverged in a wood today and I took the one less traveled. Invited. San Diego, California, US.
2024. Technological Pathways: Spatial Whole Omics Approaches. Invited. BioTechne. Bethesda, MD, US.
2022. Advancing discovery and translational research with innovations in spatial biology. Invited. Science. (Virtual), US.
2022. Through the Looking Glass. Invited. IECC 2022. (Virtual), US.
2021. 3D Spatial: A View from Leading Scientific Customers. Conference. Genomic 2.0 and MedTech Innovation Summit. (Virtual), CA, US.
2020. Introductory IMC. Conference. Expert Cytometry Webinar. (Virtual), US.
2020. Going Beyond Sight, Revealing Multiplex Biology (keynote speaker). Invited. Pathology Visions 2020. (Virtual), US.
2020. CyTOF by day, IMC by night – how to make it work, examples of projects using both MC and IMC to answer research questions. Invited. Fluidigm. (Virtual), US.
2020. Suspension by day, imaging by night: how to efficiently manage your system and optimize utilization & Fireside Data Analysis Chats. Conference. 9th Annual Mass Cytometry Summit. (Virtual), US.
2020. Genomics, Proteomics & Core Administration. Invited. ABRF 2020. Palm Springs, CA, US.
2019. Multiplexed Imaging: It's Full of Colors, Sorta. Conference. Roche. Tuscon, AZ, US.
2019. CyTOF User Group Meeting. Invited. Fluidigm. San Francisco, CA, US.
2018. Visiopharm User Group Meeting & Academy Training. Conference. Visiopharm. Denver, CO, US.
2018. Mass Cytometry. Invited. 2018 Winter Conference on Plasma Spectochemistry. Amelia Island, FL, US.
2014. Mass Cytometry with the CyTOF. Invited. GPACA, NE, US.
2014. Novel Flow Methods. Invited. DVS Sciences & University of Maryland. Baltimore, MD, US.
2014. CyTOF User's Group Meeting 2014 ~ Cytometry for the Masses, the Crowd Source Model. Conference. CyTOF User's Group Meeting 2014. Ft Lauderdale, FL, US.
2013. East CyTOF User Group Meeting. Conference. DVS Sciences. Boston, MA, US.
2012. Prognostic impact and targeting of CRM1 in acute myeloid leukemia. Invited. ASH. Atlanta, GA, US.
2012. Exosomes mediate communication between the microenvironment and leukemic cells in Acute Myeloid Leukemia. Invited. ASH. Atlanta, GA, US.

International Presentations

2025. Cellular Cartographers: Charting the Unseen with Advanced Multi-Omics. Invited. European Prostate Cancer Alliance Webinar, US.
2024. Multiplex Multi-Omics: The Future of Spatial Biology. Invited. COMET KOL Summit. Glasgow, CH.
2024. Mulitplex Multiomics: The Future of Spatial Biology. Invited. Standard Biotools. Toronto, CA.
2023. Advanced Image Analysis Techniques: High Plex Imaging Analytics on Tissue Samples. Invited. International Society for Advancement of Cytometry. Montreal, CA.
2023. Mass Cytometry Pathways. Invited. Standard Biotools. Montreal, CA.
2023. The Evolution of Spatial Biology from the perspective of a core. Invited. Lunaphore. Lausanne, CH.
2021. Spatial Proteomics: Advances in Technologies and Applications. Invited. Nature. (Virtual), CH.
2019. Playing to the Assay's Strengths. Invited. 3rd Annual Cyto User Group Meeting. Zurich, CH.
2019. CyTO 2019. Conference. Fluidigm. Vancouver, CA.
2019. Core Directors Panel. Conference. Fluidigm. Vancouver, CA.
2018. CYTO 2018 ~ Establishing Imaging Mass Cytometry in a core facility to empower highly-multiplexed tissue imaging. Conference. Fluidigm. Prague, CH.
2018. 2018 Mass Cytometry Summit ~ Slice or Dice? When to Suspend Samples for CyTOF Analysis. Invited. Fluidigm. Prague, CZ.
2017. A model for Understanding Multiplexed Imaging. Invited. Fluidigm. Zurich, CH.
2012. CYTO 2014. Invited. XXIX Congress of the International Society for Advancement of Cytometry. Ft Lauderdale, US.
2004. BV/ODV E26: modification and membrane association. Received a travel grant to attend the meeting and present. Invited. American Society for Virology. Montreal, CA.

Formal Peers

2024. Social Media Influences. Invited. Houston, TX, US.
2023. Technological Pathways: Spatial Whole Omics Approaches!. Invited. (Virtual), US.
2023. Technological Pathways: Spatial Whole Omics Approaches. Invited. Germantown, MD, US.
2022. Cellular Cartography by Mass Cytometry. Invited. Houston, TX, US.
2021. Precision Immunology Core Discussion. Invited. (Virtual), US.
2021. Cellular Cartography. Visiting. Houston, TX, US.
2021. IM-CyTOF Symposium ~ Know the FACS: Cellular Cartography by Mass Cytometry. Invited. Galveston, TX, US.
2021. High-plexed Imaging; Performing Cellular Cartography. Visiting. Houston, TX, US.
2021. "Composition or Construction" Multiplex Procedures. Invited. (virtual), US.
2021. Going Beyond Sight. Invited. (Virtual), US.
2021. IMAGING MASS CYTOMETRY: It’s for the masses!. Invited. (Virtual), US.
2020. CyTOF Application in Cancer Research. Visiting. Houston, TX, US.
2020. Research Innovation and Technology. Visiting. Houston, TX, US.
2020. FCCIF-NC and Research Imaging. Visiting. Houston, TX, US.
2020. Technical Application Webinar: Imaging Mass Cytometry (IMC). Invited. (Virtual), US.
2019. Composition vs Construction & Management, a Mass Cytometry Story. Invited. New York City, NY, US.
2019. Hyperion Imaging Mass Cytometry. Invited. Germantown, MD, US.
2018. Imaging Mass Cytometry: Why Multiplex? And How to Understand it?. Visiting. Houston, TX, US.
2018. Imaging & Mass Cytometry. Visiting. Houston, TX, US.
2017. Mass Cytometry. Visiting. Houston, TX, US.
2016. CyTOF Mass Cytometry. Invited. Galveston, TX, US.
2016. Mass Cytometry and Other Cutting Edge Technologies Available in North Campus Flow Cytometry and Cellular Imaging Core. Visiting. Houston, TX, US.
2015. The Basics of Mass Cytometry. Invited. Houston, TX, US.
2015. The Basics of Mass Cytometry. Visiting. Houston, TX, US.
2013. eHarmony in Periodic Table CyTOF. Invited. Houston, TX, US.
2013. Cytometry by Time-Of-Flight (Cy-TOF). Visiting. Houston, TX, US.
2013. Conference on Core Lab Infrastructure. Invited. Austin, TX, US.
2013. Finding Details in High Parametric Data. Visiting. Houston, TX, US.
2013. Annual Presidential Career Symposium - PhD: The Pluripotent Career. Visiting. Houston, TX, US.

Less

Grant & Contract Support

Date:	2025 - 2028
Title:	Targeting a driver kinase PCTK1 synergizes with ferroptosis inducer to combat breast cancer brain metastasis
Funding Source:	Department of Defense (DOD)
Role:	Significant Contributor
ID:	FP00022875

Date:	2025 - 2030
Title:	Elucidating roles of the CD24 ligand in early lung cancer development, immune evasion and response to KRAS-targeted therapy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	FP00023340

Date:	2025 - 2030
Title:	Elucidating roles of the CD24 ligand in lung cancer development, immune escape and response to immune-based therapy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	PA-20-185

Date:	2025 - 2030
Title:	Deciphering the role of GFPT2 in radiation-induced cardiovascular disease
Funding Source:	NIH/NCI
Role:	Significant Contributor

Date:	2025 - 2028
Title:	Elucidating the role of CD24 signaling in KRAS-mutant lung cancer development and response to KRAS-targeted therapy
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Collaborator
ID:	RP250176

Date:	2024 - 2029
Title:	3D Spatial Multi-Omics Profiling of Ovarian Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	14026665

Date:	2024 - 2025
Title:	Developing Cancer Prevention Vaccines for Lynch Syndrome Carriers
Funding Source:	Cancer Prevention Initiative (CPI)
Role:	Co-I
ID:	FP00022246

Date:	2024 - 2029
Title:	Dissecting the role of B lineage cells in mediating response of resectable lung cancer to neoadjuvant immune-based therapy
Funding Source:	NIH/NCI
Role:	Co-I
ID:	FP00019018_Res1

Date:	2024 - 2029
Title:	Interrogating the Spatial and Functional Relevance of Microbes in Pancreatic Cancer and Metastasis
Funding Source:	NIH/NCI
Role:	Significant Contributor
ID:	FP00017880_Res1

Date:	2024 - 2029
Title:	Neoadjuvant combination anti-PD-L1 and anti-TIGIT immune checkpoint blockade in Oral Cavity Squamous Cell Carcinoma
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	FP00020538

Date:	2024 - 2029
Title:	Defining the Role of Schwann Cell L1CAM-EGFR Signaling in Perineural invasion, Neuroinflammation and Cancer Associated Pain
Funding Source:	NIH/NCI
Role:	Significant Contributor
ID:	FP00015531_Res1

Date:	2024 - 2029
Title:	A 3D endometrial pre-cancer atlas with spatially-resolved cellular and molecular profiling
Funding Source:	NIH/NCI
Role:	Co-I
ID:	FP00021077

Date:	2024 - 2029
Title:	3D Spatial Multi-Omics Profiling of Ovarian Cancer
Funding Source:	NIH/NCI
Role:	Co-I
ID:	FP00021171

Date:	2024 - 2025
Title:	Immunologic consequences of HLA II dysregulation in relapsed AML post hematopoietic stem cell transplantation
Funding Source:	Ladies Leukemia League
Role:	Collaborator

Date:	2024 - 2029
Title:	Persistent BH4 depletion and vascular aging by disturbed flow
Funding Source:	NIH/NCI
Role:	Significant Contributor
ID:	GRANT13928866

Date:	2023 - 2025
Title:	Neuroendocrine Reprogramming in DSRCT Resistance Mechanisms and Treatment Strategies
Funding Source:	Department of Defense (DOD)
Role:	Significant Contributor
ID:	FP00017786

Date:	2023 - 2028
Title:	Creating therapeutic vulnerabilities in pancreatic cancer by blocking Yap1-Cox2 adaptive signaling with statin and aspirin
Funding Source:	NIH/NCI
Role:	Co-I

Date:	2023 - 2028
Title:	Persistent BH4 depletion and vascular aging by disturbed flow
Funding Source:	NIH/NCI
Role:	Significant Contributor
ID:	FP00017803

Date:	2023 - 2028
Title:	Targeting of Innate Immune Sensors for Cancer Immunotherapy
Funding Source:	NIH/NCI
Role:	Mentoring Committee Member
ID:	FP00015843_Res1

Date:	2023 - 2028
Title:	Regulation of stem-like CD8 T cells by Bone Morphogenetic Proteins in the context of resistance to immunotherapy
Funding Source:	NIH/NCI
Role:	Significant Contributor
ID:	FP00015889_Res1

Date:	2023 - 2024
Title:	Evaluating the Impact of Perioperative Antibiotic Prophylaxis and the Gut Microbiome on Systemic Immunity in Patients Undergoing Surgery for Early-Stage Melanoma
Funding Source:	American Association for Cancer Research Gertrude B. Elion Cancer Research Award
Role:	Collaborator
ID:	FP00018410

Date:	2023 - 2028
Title:	Defining the Role of L1CAM-EGFR Signaling in Head and Neck Cancer Perineural Invasion and Pain
Funding Source:	NIH/NCI
Role:	Co-I
ID:	PA-20-185

Date:	2023 - 2026
Title:	Cis-aconitate decarboxylase (ACOD1) as a therapeutic target in immunosuppressive PMN-MDSCs
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Significant Contributor
ID:	RP230084

Date:	2023 - 2026
Title:	Targeting Immune checkpoint protein B7-H3 in Breast Cancer
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Significant Contributor
ID:	FP00016924

Date:	2023 - 2026
Title:	Identifying, Understanding, and Eradicating Measurable Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)
Funding Source:	Break Through Cancer
Role:	Researcher
ID:	FP00018527

Date:	2023 - 2026
Title:	Identifying, Understanding, and Eradicating Measurable Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)
Funding Source:	Break Through Cancer
Role:	Significant Contributor
ID:	FP00018527

Date:	2023 - 2025
Title:	Aerosol Gemcitabine to enhance NK cell therapy against Osteosarcoma
Funding Source:	Children's Cancer Research Foundation
Role:	Collaborator
ID:	FP00017726

Date:	2022 - 2026
Title:	Premature aging disorders, metabolites, and atherosclerosis
Funding Source:	NIH/NCI
Role:	Significant Contributor
ID:	FP00014398_Res1

Date:	2022 - 2027
Title:	Mechanisms of Venetoclax Resistance in AML
Funding Source:	Leukemia and Lymphoma Society
Role:	Significant Contributor
ID:	SCOR-22936-22

Date:	2022 - 2027
Title:	Specialized Center of Research: An Integrated Approach towards Improving Outcomes in Higher Risk Myelodysplastic Syndromes
Funding Source:	Leukemia and Lymphoma Society
Role:	Significant Contributor
ID:	FP00016057

Date:	2022 - 2027
Title:	Acquired Resistance to Therapy and Iron (ARTI) Center
Funding Source:	NIH/NCI
Role:	Significant Contributor
ID:	U54CA274220

Date:	2022 - 2025
Title:	Integrated immuno-genomic/proteomic profiling and prediction for AML
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Significant Contributor
ID:	FP00016758

Date:	2022 - 2025
Title:	Identifying, Understanding, and Eradicating Measurable Residual Disease (MRD) in Patients with Acute Myeloid Leukemia (AML)
Funding Source:	Break Through Cancer
Role:	Significant Contributor
ID:	FP00016822

Date:	2022 - 2027
Title:	Investigating the Checkpoint Protein B7-H3 in Breast Cancer Immunotherapy
Funding Source:	NIH/NCI
Role:	Significant Contributor
ID:	FP00014974

Date:	2022 - 2027
Title:	Targeting Degradation of Programmed Death Ligand-1 for Immune Stimulation and Cancer Immunotherapy
Funding Source:	NIH/NCI
Role:	Significant Contributor

Date:	2021 - 2022
Title:	Imaging Mass Cytometry Spatial Transcriptomics via RNAscope
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	P30CA016672

Date:	2021 - 2025
Title:	Modulation of SENP2-mediated NAD+ depletion in radiation-induced endothelial damage
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	GRANT13226772

Date:	2021 - 2022
Title:	Clonal hematopoiesis drivers regulate premature aging during HIV-infetion
Funding Source:	AHA CDG award
Role:	Significant Contributor

Date:	2021 - 2022
Title:	PAR-20-114 High-End Instrumentation (HEI) Grant Program (S10) - Optofluidic Cell Sorting, Imaging, and Analytics System
Funding Source:	NIH/NCI
Role:	PI

Date:	2020 - 2023
Title:	Elucidating and therapeutic targeting of prostate bone metastasis
Funding Source:	Department of Defense (DOD)
Role:	Significant Contributor

Date:	2020 - 2025
Title:	Single Cell Spatial Analysis in Tissue
Funding Source:	NIH/NCI
Role:	PI
ID:	1R50CA243707-01A1

Date:	2020 - 2025
Title:	Effective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironment
Funding Source:	NIH/NCI
Role:	Significant Contributor

Date:	2020 - 2022
Title:	The interplay of inflammation, genomic instability, and immune microenvironment in oral cancer development
Funding Source:	NIH/NCI
Role:	Significant Contributor

Date:	2020 - 2025
Title:	Modulation Of The Glioblastoma Immune Landscape With STING
Funding Source:	NIH/NCI
Role:	Significant Contributor

Date:	2020 - 2025
Title:	Deciphering the gene regulatory networks and biophysical cues that sustain high-grade osteosarcoma
Funding Source:	NIH/NCI
Role:	Significant Contributor

Date:	2020 - 2025
Title:	Deciphering the radiogenomic and immunologic alterations that drive progression to invasive breast cancer
Funding Source:	NIH/NCI
Role:	Significant Contributor

Date:	2020 - 2024
Title:	SUMOylation and SEPA (senescence and endothelial pro-inflammatory activation)
Funding Source:	National Heart, Lung and Blood Institute
Role:	Significant Contributor

Date:	2020 - 2024
Title:	Clonal hematopoiesis drivers and trained innate immunity
Funding Source:	National Heart, Lung and Blood Institute
Role:	Significant Contributor

Date:	2020 - 2024
Title:	Endothelial TOP2beta and radiation-induced atherosclerosis
Funding Source:	NIH/NCI
Role:	Significant Cntributor

Date:	2020 - 2025
Title:	Effective combination therapy for MTAP-deficient bladder carcinoma by targeting metabolic vulnerability and modulating tumor immune microenvironment
Funding Source:	NIH/NCI
Role:	Significant Contributor

Date:	2020 - 2025
Title:	Microdevice-enabled High Throughput Intratumoral Drug Testing For Ewing Sarcoma
Funding Source:	NIH/NCI
Role:	Significant Contributor

Date:	2020 - 2023
Title:	Targeting TAZ mediated proneural to mesenchymal transition in malignant gliomas
Funding Source:	Department of Defense (DOD)
Role:	Significant Contributor

Date:	2020 - 2022
Title:	Predictive multiplex assay for targets of antibody-drug conjugates and immunotherapies to evaluate therapeutic options for patients with rare tumors
Funding Source:	NIH/NCI
Role:	Significant Contributor

Date:	2020 - 2024
Title:	TOP2b, telomere dysfunction phenotype, and radiation-induced cardiovascular disease
Funding Source:	NIH/NCI
Role:	Significant Contributor

Date:	2020 - 2025
Title:	Clonal hematopoiesis drivers induce senescent phenotype by topoisomerase 2B degradation
Funding Source:	NIH/NCI
Role:	Significant Contributor

Date:	2020 - 2023
Title:	Evolution of the immune microenvironment as determinants of breast ductal carcinoma in situ progression
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Significant Contributor

Date:	2020 - 2022
Title:	Targeting macrophage polarization switch for prevention of breast cancer
Funding Source:	Prevent Cancer Foundation
Role:	Significant Contributor

Date:	2019 - 2020
Title:	Evolution of the immune microenvironment as determinants of breast ductal carcinoma in situ progression
Funding Source:	Department of Defense (DOD)
Role:	Significant Contributor

Date:	2019 - 2026
Title:	Cancer Center Support Grant, PP-SR-12; Flow Cytometry and Cellular Imaging Facility
Funding Source:	NIH/NCI
Role:	Co-Director of Shared Resource Core Facility
ID:	5P30 CA016672

Date:	2019 - 2019
Title:	Multiplex predictive assay for antibody-drug conjugate targets in patients with rare tumors
Funding Source:	ELSA U PARDEE FOUNDATION
Role:	Significant Collaborator

Date:	2018 - 2023
Title:	Combating Intratumoral Cancer Cell Heterogeneity in Ewing Sarcoma by Co-targeting the EWS-FLI1 Fusion Protein and Epigenetic Mediators of Resistance; Core 2: Image Mass CyToF Core
Funding Source:	NIH/NCI
Role:	Core Director
ID:	1U54CA232242-01

Date:	2015 - 2016
Title:	Understanding the role of mesenchymal stromal cells in a rodent model of liver
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Investigator

Date:	2014 - 2015
Title:	New Technology Implementation in Shared Resources: FCCIF Web Analysis Tool
Funding Source:	NIH/NCI
Role:	PI
ID:	5 P30 CA016672

Date:	2013 - 2014
Title:	New Technology Implementation in Shared Resources, CyTOF Single Cell Proteomics
Funding Source:	NIH/NCI
Role:	Collaborator
ID:	5P30 CA016672

Date:	2013 - 2014
Title:	New Technology Implementation in Shared Resources, Establishment and Validation of Single Cell RNA Flow
Funding Source:	NIH/NCI
Role:	Co-I
ID:	5P30 CA016672

Date:	2012 - 2017
Title:	Single cell network analysis through interactive manipulation of very high parameter data
Funding Source:	NIH/NIBIB
Role:	Co-I

Date:	2012 - 2015
Title:	CyTOF Mass Cytometer and Element Tagging System
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Research Scientist
ID:	RP121010

Date:	2010 - 2015
Title:	MSC MIRA-CPRIT Flow Cytometry and Cellular Imaging Core B
Funding Source:	Cancer Prevention & Research Institute of Texas (CPRIT)
Role:	Co-I
ID:	RP101346

Date:	2009 - 2010
Title:	Advantages of Multiphoton Confocal FV1000MPE in Cancer Biology Research
Funding Source:	NIH/NCI
Role:	Research Scientist
ID:	1 S10 RR029400-01

Title:	Optofluidic Cell Sorting, Imaging, and Analytic System
Funding Source:	NIH/NCI
Role:	PI
ID:	FP#00011230_Res1

Title:	Deciphering the GRNs and biophysical cues that sustain high-grade osteosarcoma
Funding Source:	NIH/NCI
Role:	Significant Contriboutor
ID:	PAR-19-158

Title:	Modeling TIME Architecture by Radiomics to Quantify Response to IO Agents
Funding Source:	Melanoma Research Alliance
Role:	Co-I

Title:	Modulation of SENP2-mediated NAD+ depletion in radiation-induced endothelial damage
Funding Source:	METHODIST HOSPITAL RESEARCH INSTITUTE
Role:	Significant Contributor

Title:	Elucidating and therapeutic targeting of prostate bone metastasis
Funding Source:	USA Medical Research Acq Activity
Role:	Significant Contributor

Title:	Integrative genomic analysis to decode the spatial context associated with chemoresistance in high-grade serous ovarian cancer
Funding Source:	NIH/NCI
Role:	Significant Contributor

Title:	Delineating Single Cell Level Intra-Tumoral Heterogeneity and Validating It's Association with Chemoradiation Responses in Esophageal Adenocarcinoma
Funding Source:	Department of Defense (DOD)
Role:	Significant Contributor
ID:	FP00014652

CV information above last modified June 16, 2025

Jared K. Burks, Ph.D.

About Dr. Burks

Spatial biology with Dr. Jared Burks

Present Title & Affiliation

Primary Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Editorials

Abstracts

Book Chapters

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Help #EndCancer

Jared K. Burks, Ph.D.

About Dr. Burks

Spatial biology with Dr. Jared Burks

Present Title & Affiliation

Primary Appointment

Research Interests

Education & Training

Degree-Granting Education

Postgraduate Training

Experience & Service

Other Appointments/Responsibilities

Institutional Committee Activities

Honors & Awards

Professional Memberships

Selected Publications

Peer-Reviewed Articles

Invited Articles

Other Articles

Editorials

Abstracts

Book Chapters

Selected Presentations & Talks

Local Presentations

Regional Presentations

National Presentations

International Presentations

Formal Peers

Grant & Contract Support

Patient Reviews

Request an Appointment

Related Links

Care Centers and Clinics

Departments and Divisions

Labs

Clinical Trials

Help #EndCancer

Give Now

Donate Blood

Volunteer